Original Article
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
N Engl J Med 2008; 358:2560-2572June 12, 2008
- Abstract
Background
In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain.
Methods
We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or less. Primary end points were composites of major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) and major microvascular events (new or worsening nephropathy or retinopathy), assessed both jointly and separately.
Results
After a median of 5 years of follow-up, the mean glycated hemoglobin level was lower in the intensive-control group (6.5%) than in the standard-control group (7.3%). Intensive control reduced the incidence of combined major macrovascular and microvascular events (18.1%, vs. 20.0% with standard control; hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; P=0.01), as well as that of major microvascular events (9.4% vs. 10.9%; hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), primarily because of a reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006), with no significant effect on retinopathy (P=0.50). There were no significant effects of the type of glucose control on major macrovascular events (hazard ratio with intensive control, 0.94; 95% CI, 0.84 to 1.06; P=0.32), death from cardiovascular causes (hazard ratio with intensive control, 0.88; 95% CI, 0.74 to 1.04; P=0.12), or death from any cause (hazard ratio with intensive control, 0.93; 95% CI, 0.83 to 1.06; P=0.28). Severe hypoglycemia, although uncommon, was more common in the intensive-control group (2.7%, vs. 1.5% in the standard-control group; hazard ratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001).
Conclusions
A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.)
Media in This Article
Figure 1
Enrollment, Randomization, and Follow-up of Study Participants.Figure 2
Glucose Control at Baseline and during Follow-up, According to Glucose-Control Strategy.Article Activity
- Article
The prevalence of diabetes is increasing worldwide, and most people with diabetes will die or be disabled as a consequence of vascular complications.1,2 Prospective studies have shown continuous associations of blood glucose and glycated hemoglobin levels with the risks of major vascular events.3,4 However, previous randomized trials evaluating the effects of glycemic control in patients with diabetes have provided inconsistent evidence of effects on vascular disease.5-11 Nevertheless, current guidelines recommend a target glycated hemoglobin level of 7.0% or less for most patients with diabetes.12-14
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial was designed to assess the effects on major vascular outcomes of lowering the glycated hemoglobin value to a target of 6.5% or less in a broad cross-section of patients with type 2 diabetes. The part of the study that evaluated the lowering of blood pressure with the use of perindopril and indapamide, completed in June 2007, showed a reduction in the risks of major vascular events and death, regardless of the initial blood pressure.15 Here we report the main results from the comparison of the blood-glucose-lowering strategies, completed in January 2008, which evaluated an intensive glucose-control strategy based on gliclazide (modified release) and other drugs as required to achieve the target glycated hemoglobin level.
Methods
The ADVANCE trial is a factorial randomized, controlled trial conducted at 215 collaborating centers in 20 countries from Asia, Australasia, Europe, and North America (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). Approval to conduct the trial was obtained from the ethics committee of each study center, and all participants provided written informed consent. Detailed study methods have been published previously.16
The ADVANCE trial was an investigator-initiated trial that was designed, conducted, analyzed, and had data interpreted independently of both sponsors. Study data were collected and retained by the investigators and were not made available to the study sponsors. The writing committee and the management committee, whose membership did not include any sponsor representatives, had final responsibility for the manuscript preparation and the decision to submit for publication. The first five authors vouch for the validity and completeness of the reported data.
Participants
Eligibility criteria, as detailed previously,16 were a diagnosis of type 2 diabetes mellitus at 30 years of age or older, an age of at least 55 years at the time of study entry, and a history of major macrovascular or microvascular disease or at least one other risk factor for vascular disease. There were no inclusion or exclusion criteria related to glycated hemoglobin. Exclusion criteria included a definite indication for, or contraindication to, any of the study treatments or a definite indication for long-term insulin therapy at the time of study entry.
Study Treatment
Potentially eligible participants entered a 6-week run-in period, during which they continued their usual methods of glucose control and received a fixed combination of perindopril and indapamide. Those who tolerated and were compliant with the treatment during the run-in period were randomly assigned, according to a factorial design, to receive continued therapy with either perindopril and indapamide or matching placebo and to undergo either a strategy of intensive blood glucose control (target glycated hemoglobin value, ≤6.5%) or a strategy of standard glucose control (with target glycated hemoglobin levels defined on the basis of local guidelines). Central, computer-based randomization was stratified according to several factors,16 including study center and presence or absence of a history of major vascular disease.
Patients who were randomly assigned to undergo intensive glucose control were given gliclazide (modified release, 30 to 120 mg daily) and were required to discontinue any other sulfonylurea. Although the timing, selection, and doses of all other treatments were at the discretion of the treating physician, a treatment protocol was suggested (see the Supplementary Appendix). On the basis of the glycated hemoglobin level at each visit, this protocol initially advised increasing the dose of gliclazide (modified release), with the sequential addition or increase in dose of metformin, thiazolidinediones, acarbose, or insulin (advising the initial use of basal insulin, with the addition of short-acting insulin at meals for patients in whom the target glycated hemoglobin level was not achieved, despite acceptable fasting blood glucose levels). Patients in the standard-control group who were using gliclazide (modified release) when they entered the study were required to substitute this drug with another sulfonylurea, if continued therapy was required.
Follow-up Schedule
Patients in the intensive-control group were seen at week 2 after randomization; then at months 1, 2, 3, 4, and 6; and every 3 months thereafter. These patients were also encouraged to attend other, unscheduled visits to improve the monitoring and intensification of glucose control. Participants assigned to undergo standard control were seen at 3, 4, and 6 months after randomization and every 6 months thereafter. At study visits common to both groups, information was collected on blood glucose, glycated hemoglobin, blood pressure, and lipids, as well as adherence to, and tolerability of, study treatments and occurrence of study outcomes. At the 2-year, 4-year, and final visits, the ratio of urinary albumin to creatinine was measured and a retinal examination, the Mini–Mental State Examination, and quality-of-life assessment were also performed. At study visits for patients in the intensive-control group only, the information collected was limited to blood glucose, glycated hemoglobin, and glucose-lowering treatments.
Laboratory Measurements
All measurements were performed in local laboratories, and each glycated hemoglobin measurement was standardized (see the Supplementary Appendix).17 Blood glucose measurements were performed on samples of venous or capillary blood, depending on local practice.
End Points
The primary study outcomes were a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately. Macrovascular events were defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Microvascular events were defined as new or worsening nephropathy (i.e., development of macroalbuminuria, defined as a urinary albumin:creatinine ratio of more than 300 μg of albumin per milligram of creatinine [33.9 mg per millimole], or doubling of the serum creatinine level to at least 200 μmol per liter [2.26 mg per deciliter], the need for renal-replacement therapy, or death due to renal disease) or retinopathy (i.e., development of proliferative retinopathy, macular edema or diabetes-related blindness or the use of retinal photocoagulation therapy).
Prespecified secondary outcomes were death from any cause, death from cardiovascular causes, major coronary events (death due to coronary heart disease [including sudden death] or nonfatal myocardial infarction), total coronary events (major coronary events, silent myocardial infarction, coronary revascularization, or hospital admission for unstable angina), major cerebrovascular events (death due to cerebrovascular disease or nonfatal stroke), total cerebrovascular events (major cerebrovascular events, transient ischemic attack, or subarachnoid hemorrhage), heart failure (death due to heart failure, hospitalization for heart failure, or worsening New York Heart Association class), peripheral vascular events, all cardiovascular events, new or worsening nephropathy, new or worsening retinopathy, development of microalbuminuria (urinary albumin:creatinine ratio, 30 to 300 μg per milligram [0.34 to 33.9 mg per millimole]), visual deterioration, new or worsening neuropathy, decline in cognitive function (reduction in the Mini–Mental State Examination score by at least 3 points, as compared with the baseline score), dementia (satisfying the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition), and hospitalization for 24 hours or more. Hypoglycemia was defined as a blood glucose level of less than 2.8 mmol per liter (50 mg per deciliter) or the presence of typical symptoms and signs of hypoglycemia without other apparent cause. Patients with transient dysfunction of the central nervous system who were unable to treat themselves (requiring help from another person) were considered to have severe hypoglycemia.
An independent End Point Adjudication Committee, unaware of the group assignments, reviewed source documentation for all suspected primary end points and deaths. An independent data and safety monitoring committee reviewed the unblinded data at regular intervals.
Statistical Analysis
The ADVANCE trial was originally designed to have a statistical power of 90% to detect a relative risk reduction of 16% or more for intensive control, as compared with standard control, for each of the primary outcomes, with the use of a two-tailed test with an alpha level of 5%. After a mean of approximately 3 years of follow-up, it became apparent that the event rates (in the two groups combined) were lower than expected. Thus, in a manner blinded to any results of the effects of intervention, two changes were made to the protocol to increase the power of the study: joint (as well as separate) analysis of the primary outcomes was prespecified, and the period of treatment and follow-up was extended by 12 months for the part of the study that evaluated the lowering of blood pressure and by 18 months for the part that evaluated the control of blood glucose.
All analyses were conducted according to the intention-to-treat principle. Effects of treatment on study end points were estimated with the use of unadjusted Cox proportional-hazard models, involving survival time to the first relevant end point in any individual patient. Data for patients were censored at their date of death, date of last visit (for those still alive at the end of the follow-up period), or date when last known to be alive (for those with unknown vital status). Differences in continuous variables between the two study groups during the follow-up period were estimated with the use of linear mixed models. The numbers needed to treat were calculated as reciprocals of the absolute differences in risk with their normally approximated 95% confidence intervals.18 All P values were two-sided, and P values less than 0.05 were considered to indicate statistical significance. No adjustment for multiple statistical testing was made.19
The homogeneity of treatment effects across subgroups (none of which were prespecified) was tested by adding interaction terms to the relevant Cox models. Interaction between the blood-pressure intervention and the blood-glucose intervention in the ADVANCE trial was assessed with the use of the database locked at the end of the period of follow-up for the blood-pressure-lowering part of the study (average duration of follow-up, 4.3 years). All analyses were performed with the use of SAS software, version 9.1 (SAS Institute).
Results
Enrollment and Baseline Characteristics of Participants
Between June 2001 and March 2003, a total of 12,877 potentially eligible participants were registered, 1737 (13.5%) were withdrawn during the run-in period, and 11,140 (86.5%) underwent randomization (Figure 1Figure 1
Enrollment, Randomization, and Follow-up of Study Participants.). The median duration of follow-up was 5.0 years. The two groups had similar characteristics at baseline (Table 1Table 1
Characteristics of Participants at Baseline and at the End of the Follow-up Period., and Table 1 in the Supplementary Appendix). The mean baseline glycated hemoglobin was 7.5%, and the mean fasting blood glucose level was 8.5 mmol per liter (153 mg per deciliter). At baseline, 91% of patients were receiving oral hypoglycemic agents.Effects on Glycated Hemoglobin and Fasting Blood Glucose
At the end of the follow-up period, the mean glycated hemoglobin values were 6.5% in the intensive-control group and 7.3% in the standard-control group. During the follow-up period, the time-weighted average glycated hemoglobin level was reduced by 0.67 percentage point and the fasting blood glucose level by 1.2 mmol per liter (21.9 mg per deciliter) among patients undergoing intensive control as compared with those undergoing standard control (Figure 2Figure 2
Glucose Control at Baseline and during Follow-up, According to Glucose-Control Strategy.).Effects on Other Risk Factors
Table 1 describes the levels of other risk factors among study participants. At the end of the follow-up period, the mean systolic blood pressure was lower in the intensive-control group than in the standard-control group (135.5 vs. 137.9 mm Hg; average difference, 1.6 mm Hg; P<0.001) (Table 1). This difference was apparent at the first common post-randomization visit (at 3 months) and all subsequent common visits (Fig. 1 in the Supplementary Appendix). The mean body weight during the follow-up period was 0.7 kg greater in the intensive-control group than in the standard-control group (P<0.001).
Use of Glucose-Lowering Therapy and Other Treatments
On average, each patient in the intensive-control group attended 31 study visits, as compared with 11 for each patient in the standard-control group, over the course of the trial period. During the follow-up period, the use of most classes of oral hypoglycemic drug and of insulin had increased to a greater degree in the intensive-control group than in the standard-control group (Table 1, and Table 1 in the Supplementary Appendix). In the intensive-control group, 90% of patients attending the final visit were still receiving gliclazide (modified release), 70.4% of whom were taking 120 mg of the drug daily. Insulin was prescribed for 40.5% and 24.1% of patients in the intensive-control group and the standard-control group, respectively, by the end of the follow-up period. At the final visit, 16.8% of patients undergoing intensive glucose control and 10.9% of those undergoing standard glucose control were receiving thiazolidinediones. The use of blood-pressure–lowering, lipid-modifying, and antiplatelet treatments was similar between the two groups during the follow-up period.
Effects on Primary Outcomes
A total of 2125 participants had a major macrovascular or microvascular event: 18.1% in the intensive-control group and 20.0% in the standard-control group (hazard ratio, 0.90; 95% confidence interval (CI), 0.82 to 0.98; P=0.01) (Figure 3Figure 3
Cumulative Incidences of Events, According to Glucose-Control Strategy.). Thus, it was estimated that such an event would be averted during a 5-year period in 1 of every 52 participants (95% CI, 30 to 213) undergoing intensive control. As compared with standard control, intensive control resulted in a significant reduction in the incidence of major microvascular events (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01) but not in the incidence of major macrovascular events (hazard ratio, 0.94; 95% CI, 0.84 to 1.06; P=0.32). There was no evidence of an interaction between the blood-pressure intervention and the blood-glucose intervention in the ADVANCE trial for the primary outcomes (P>0.50 for all comparisons).Effects on Death and Other Secondary Outcomes
A total of 1031 participants died: 8.9% in the intensive-control group and 9.6% in the standard-control group (hazard ratio, 0.93; 95% CI, 0.83 to 1.06; P=0.28) (Figure 3). As compared with standard control, intensive control was associated with a significant reduction in renal events, including new or worsening nephropathy (hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006) and new-onset microalbuminuria (hazard ratio, 0.91; 95% CI, 0.85 to 0.98; P=0.02) (Figure 4Figure 4
Relative Effects of Glucose-Control Strategy on All Prespecified Primary and Secondary Outcomes.). The component of new or worsening nephropathy most clearly reduced through intensive glucose control was the development of macroalbuminuria (2.9%, vs. 4.1% with standard control; hazard ratio, 0.70; 95% CI, 0.57 to 0.85; P<0.001), with a trend toward a reduction in the need for renal-replacement therapy or death from renal causes (0.4% vs. 0.6%; hazard ratio, 0.64; 95% CI, 0.38 to 1.08; P=0.09) but no effect on the doubling of serum creatinine level (1.2% vs. 1.1%; hazard ratio, 1.15; 95% CI, 0.82 to 1.63; P=0.42). More patients undergoing intensive control were hospitalized for any cause (44.9%, vs. 42.8% of those in the standard-control group; hazard ratio, 1.07; 95% CI, 1.01 to 1.13; P=0.03), with some of the excess of hospitalizations due to severe hypoglycemia (1.1% vs. 0.7%; odds ratio, 1.52; 95% CI, 1.01 to 2.28; P=0.04). There were no significant differences between the two groups for any of the other prespecified secondary outcomes (Figure 4).Effects on Hypoglycemia
Severe hypoglycemia occurred more frequently in the intensive-control group than in the standard-control group: 150 patients (2.7%) undergoing intensive control had at least one severe hypoglycemic episode, as compared with 81 patients (1.5%) undergoing standard control (hazard ratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001). These included one fatal episode in the standard-control group and one episode resulting in permanent disability in each group. On average, the rate of severe hypoglycemic events was 0.7 event per 100 patients per year in the intensive-control group and 0.4 event per 100 patients per year in the standard-control group. Minor hypoglycemia also occurred more frequently in patients undergoing intensive control (120 events per 100 patients per year, vs. 90 with standard control). Approximately 47% of patients in the intensive-control group and 62% of those in the standard-control group remained free of any hypoglycemic event during the follow-up period.
Effects in Subgroups of Patients
The effects of intensive control on major vascular events were consistent across participant subgroups, as defined by a range of baseline characteristics (P for heterogeneity, ≥0.10 for all comparisons) (Figure 5Figure 5
Effects of Glucose-Control Strategy on Combined Major Macrovascular and Microvascular Events, According to Baseline Characteristics.).Discussion
In the ADVANCE trial, an intensive glucose-control strategy involving gliclazide (modified release), and other drugs as required, lowered the average glycated hemoglobin value to 6.5% in a broad range of patients with type 2 diabetes and reduced the incidence of the combined primary outcome of major macrovascular or microvascular events. The main contributor to the 10% relative reduction in the primary outcome found with intensive control as compared with standard control was a 21% relative reduction in the risk of new or worsening nephropathy. There was no evidence of a reduction in macrovascular events. Intensive glucose control was associated with an increased risk of severe hypoglycemia and an increased rate of hospitalization, as compared with standard control. There was no evidence that the effects of intensive glucose control were dependent on the baseline glycated hemoglobin or blood glucose level, age, sex, or presence or absence of a history of vascular disease.
There were no significant differences between the two study groups in the rate of death from any cause or death from cardiovascular causes. These findings contrast with the reported excess mortality that led to premature termination of the intensive glucose-control strategy in another large, randomized trial involving patients with type 2 diabetes (Action to Control Cardiovascular Risk in Diabetes [ACCORD]; ClinicalTrials.gov number, NCT00000620), in which similar levels of glucose control were achieved with the intensive-control strategy.20,21 Mechanisms speculated to underlie the excess mortality found with intensive glucose control in the ACCORD trial include the initial level of glycated hemoglobin, the degree and pace of glucose lowering, and the treatments used to achieve such lowering.20,22 In the ADVANCE trial, no subgroup of participants was identified to have evidence of an adverse effect of intensive glucose lowering on major vascular outcomes, including the subgroup with an initial median glycated hemoglobin value similar to that in the ACCORD study population.21
Intensive glucose control in the ADVANCE trial resulted in a reduction by one fifth in the development of new or worsening nephropathy and a more modest, though significant, reduction in that of new-onset microalbuminuria. In the U.K. Prospective Diabetes Study (UKPDS), the largest previously reported randomized trial of glycemic control in patients with type 2 diabetes, tighter glucose control did not reduce the incidence of major renal outcomes, although there was some evidence of a reduction in the development of microalbuminuria and overt proteinuria with a prolonged follow-up period.6 The clear reduction in nephropathy demonstrated in the ADVANCE trial is important, because indexes of renal impairment are strongly associated with the future risk of major vascular events, end-stage renal disease, and death in patients with diabetes.23,24
There is no evidence that intensive glucose control in the ADVANCE trial led to reduced new or worsening retinopathy, including retinal photocoagulation. The lower rate of retinal photocoagulation in the ADVANCE trial than in previous studies of diabetes7,25 was also reported in another recent trial.26 This low event rate limited the power of the study to detect any moderate effects of the intervention on microvascular eye disease. However, more evidence about the retinovascular effects of intensive glucose control will be provided by the ADVANCE retinal imaging substudy.27
The ADVANCE trial did not show a significant effect of intensive glucose control on the risk of major macrovascular events. Although the results may indicate that lowering blood glucose levels to an average glycated hemoglobin level of 6.5% with the treatments used does not reduce the risk of macrovascular events, the results do not preclude a benefit of the size predicted by the achieved difference between the intensive-control group and the standard-control group in glycated hemoglobin levels. From observational data describing the association between glycated hemoglobin and cardiovascular events and a meta-analysis of previous randomized trials of glycemic control,4,10 a 0.7% reduction in the glycated hemoglobin value might be expected to produce a reduction in the rate of macrovascular events by approximately one sixth. The confidence intervals for the estimate of the effect of treatment on macrovascular events in the ADVANCE trial are consistent with such a reduction, but the ADVANCE trial did not have adequate statistical power to detect such an effect reliably. The annual rate of macrovascular events (2.2%) was lower than the anticipated rate of 3.0% based on previous studies of patients with type 2 diabetes,7,25 possibly as a consequence of the greater use of statins, blood-pressure–lowering drugs, and antiplatelet agents. Future combined analyses of the ADVANCE trial, the ACCORD trial, and other studies should provide further insight into the effects of intensive glucose control on macrovascular events.21,28
In the part of the ADVANCE trial evaluating the lowering of blood pressure,15 a reduction of 5.6 mm Hg in the systolic blood pressure among patients randomly assigned to receive perindopril and indapamide, as compared with those assigned to receive placebo, resulted in a relative risk reduction of 9% for the primary combined outcome. Thus, the expected relative risk reduction associated with a 1.6 mm Hg reduction in systolic blood pressure would be less than 3%. This suggests that the lower blood pressure among patients undergoing intensive glucose control probably explains some, but no more than one quarter to one third, of the 10% reduction seen with intensive glucose control as compared with standard control. The explanation for the reduction in blood pressure in the intensive-control group is unclear. The difference in blood pressure so soon after randomization may indicate an early effect of the study treatment regimen.29-31 However, it is also possible that the difference reflects nonspecific effects associated with more frequent contact with health care providers.
As expected, there was a significantly higher incidence of hypoglycemia in the intensive-control group (three additional severe events for every 1000 patients treated for 1 year), although the overall risk of this complication was low. Almost half of all patients undergoing intensive control remained free from any hypoglycemia (severe or minor) during the follow-up period. The proportion of patients with at least one severe hypoglycemic episode each year was about one quarter that observed in the UKPDS,6 despite the lower glycated hemoglobin levels among the ADVANCE participants.
In the ADVANCE trial, an intensive glucose-control strategy involving gliclazide (modified release) and other glucose-lowering drugs as required reduced the glycated hemoglobin level to an average of 6.5%. There was no evidence that this treatment strategy increased mortality.20,21 Intensive glucose control significantly reduced the primary composite outcome of major macrovascular or microvascular events, mainly as a consequence of a reduction in nephropathy. There was no separately significant reduction in major macrovascular events, although a modest benefit could not be ruled out. However, it is clear that the prevention of macrovascular complications of diabetes requires a multifactorial approach32 addressing all major modifiable risk factors, including blood pressure33 and blood lipids.34 The main benefit conferred by the ADVANCE treatment regimen was a one-fifth reduction in renal complications, indicating that intensive control of glucose has an important role in the prevention of microvascular complications of type 2 diabetes.
Supported by grants from Servier (the major financial sponsor) and the National Health and Medical Research Council of Australia (211086 and 358395). Servier manufactures gliclazide (modified release) and the fixed combination of perindopril and indapamide.
Dr. Patel reports receiving lecture fees from Servier, Pfizer, and Abbott and grant support from Pfizer, Servier, and Sanofi-Aventis; Dr. MacMahon, being a member of advisory boards for Servier, Pfizer, and Novartis and receiving lecture fees from Servier and Pfizer and research grants from Servier, Pfizer, and Novartis; Dr. Chalmers, being a member of an advisory board for Servier and receiving lecture fees from Servier, Pfizer, and Daiichi and grant support from Servier; Dr. Neal, receiving lecture fees from Servier and GlaxoSmithKline and research grants from Pfizer; Dr. Woodward, receiving consulting fees from Pfizer, lecture fees from Servier and Pfizer, and grant support from Pfizer and Sanofi-Aventis; Dr. Marre, receiving lecture fees from Servier and being a member of advisory boards for Servier, Novo Nordisk, and Sanofi-Aventis; Dr. Cooper, receiving consulting fees from Merck, GlaxoSmithKline, Amgen, and AstraZeneca and lecture fees from Servier; Dr. Grobbee, receiving lecture fees from Servier and consulting and lecture fees and grant support from Pfizer, AstraZeneca, Novartis, and Sanofi-Aventis; Dr. Hamet, receiving consulting fees from Servier, Neurochem, Prognomix, Medpharmgene, Novartis, Bristol-Myers Squibb, Pfizer, and Boehringer Ingelheim; lecture fees from Servier, Novartis, Pfizer, and Bristol-Myers Squibb; and grant support from Pfizer; Dr. Harrap, receiving lecture fees from Servier; Dr. Heller, receiving consulting fees from Novo Nordisk, Eli Lilly, and Amylin; lecture fees from Novo Nordisk, Eli Lilly, Servier, and Merck; and grant support from Novo Nordisk and GW Pharmaceuticals; Dr. Mancia, receiving consulting and lecture fees from Servier, Novartis, Bayer, Boehringer Ingelheim, Merck, and Sanofi-Aventis; Dr. Mogensen, receiving lecture fees from Servier; Dr. Pan, receiving lecture fees from Servier, Bayer, Novo Nordisk, Bristol-Myers Squibb, Pfizer, and Sanofi-Aventis; Dr. Poulter, receiving consulting fees from Gilead, Bristol-Myers Squibb, Sanofi-Aventis, Daiichi Sankyo, Merck, Preventicum, and Pfizer; lecture fees from Servier, Novartis, Pfizer, Bristol-Myers Squibb, and Sanofi-Aventis; and grant support from Servier, Pfizer, Mars, and Menarini; Dr. Rodgers, receiving lecture fees from Pfizer and Merck and grant support from Dr. Reddy's Laboratories; Dr. Williams, receiving consulting fees from Pfizer, Merck, and Novartis; lecture fees from Servier, Pfizer, Merck, and Novartis; and grant support from Boehringer Ingelheim and Pfizer; and Dr. Travert, receiving lecture fees from Servier. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0802987) was published at www.nejm.org on June 6, 2008.
Source Information
Address reprint requests to Dr. Anushka Patel at the Cardiovascular Division, George Institute for International Health, University of Sydney, P.O. Box M201, Missenden Rd., Sydney, NSW 2050, Australia, or at apatel@george.org.au.
Members of the ADVANCE Collaborative Group are listed in the Supplementary Appendix (available with the full text of this article at www.nejm.org).
Appendix
The members of the Writing Committee of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group (Anushka Patel, M.D., Ph.D., Stephen MacMahon, D.Sc., Ph.D., John Chalmers, M.D., Ph.D., Bruce Neal, M.D., Ph.D., and Laurent Billot, M.Sc., the George Institute for International Health and University of Sydney, Sydney; Mark Woodward, Ph.D., the George Institute for International Health and University of Sydney, Sydney, and Mount Sinai School of Medicine, New York; Michel Marre, M.D., Ph.D., Hôpital Bichat–Claude Bernard and Université Paris 7, Paris; Mark Cooper, M.D., Ph.D., Baker Heart Research Institute, Melbourne, Australia; Paul Glasziou, M.D., Ph.D., University of Oxford, Oxford, United Kingdom, and University of Queenland, Brisbane, Australia; Diederick Grobbee, M.D., Ph.D., Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Pavel Hamet, M.D., Ph.D., Centre Hospitalier de l'Université de Montreal and Université de Montreal, Montreal; Stephen Harrap, M.D., Ph.D., University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Simon Heller, M.D., University of Sheffield and Sheffield Teaching Hospitals National Health Service (NHS) Foundation Trust, Sheffield, United Kingdom, Lisheng Liu, M.D., Chinese Hypertension League Institute, Beijing; Giuseppe Mancia, M.D., Ph.D., University of Milan–Bicocca and San Gerardo Hospital, Milan; Carl Erik Mogensen, M.D., Medical Department M, Aarhus Sygehus, Aarhus, Denmark; Changyu Pan, M.D., Chinese People's Liberation Army General Hospital, Beijing; Neil Poulter, M.D., Imperial College and St. Mary's Hospital, London; Anthony Rodgers, M.D., Ph.D., Clinical Trials Research Unit and University of Auckland, Auckland, New Zealand; Bryan Williams, M.D., Ph.D., University of Leicester School of Medicine and Leicester Royal Infirmary, Leicester, United Kingdom; Severine Bompoint, B.Sc., the George Institute for International Health, Sydney; Bastiaan E. de Galan, M.D., Ph.D., the George Institute for International Health, Sydney, and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; Rohina Joshi, M.D., Ph.D., the George Institute for International Health and University of Sydney, Sydney; and Florence Travert, M.D., Hôpital Bichat–Claude Bernard and Université Paris 7, Paris) assume responsibility for the overall content and integrity of the article.
- References
References
1
Moss SE ,Klein R ,Klein BE . Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158-1162
CrossRef | Web of Science | Medline2
Fox CS ,Coady S ,Sorlie PD , et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1544-1550
CrossRef | Web of Science | Medline3
Moss SE ,Klein R ,Klein BE ,Meuer SM . The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994;154:2473-2479
CrossRef | Web of Science | Medline4
Selvin E ,Marinopoulos S ,Berkenblit G , et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-431
Web of Science | Medline5
Shichiri M ,Kishikawa H ,Ohkubo Y ,Wake N . Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetes patients. Diabetes Care 2000;23:Suppl 2:B21-B29
Web of Science | Medline6
UK Prospective Diabetes Study (UKPDS) Group
CrossRef | Web of Science | Medline7
UK Prospective Diabetes Study (UKPDS) Group
CrossRef | Web of Science | Medline8
Abraira C ,Colwell J ,Nuttall F , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med 1997;157:181-188
CrossRef | Web of Science | Medline9
Ohkubo Y ,Kishikawa H ,Araki E , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
CrossRef | Web of Science | Medline10
Stettler C ,Allemann S ,Juni P , et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38
CrossRef | Web of Science | Medline11
Meinert CL ,Knatterud GL ,Prout TE ,Klimt CR . A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:Suppl:789-830
Web of Science | Medline12
American Diabetes Association
Medline13
IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
14
Ryden L ,Standl E ,Bartnik M , et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136
CrossRef | Web of Science | Medline15
Patel A, ADVANCE Collaborative Group, MacMahon S, et al
CrossRef | Web of Science | Medline16
ADVANCE Management Committee
CrossRef | Web of Science | Medline17
Wales External Quality Assurance Scheme home page. (Accessed May 19, 2008, at http://www.weqas.com.)
18
Woodward M. Epidemiology: study design and data analysis. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC Press, 2005.
19
Schulz KF ,Grimes DA . Multiplicity in randomised trials. I. Endpoints and treatments. Lancet 2005;365:1591-1595
CrossRef | Web of Science | Medline20
National Institutes of Health. For Safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease. 2008. (Accessed May 19, 2008, at http://www.nih.gov/news/health/feb2008/nhlbi-06.htm.)
21
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group
Full Text | Web of Science | Medline22
Home P . Safety of very tight blood glucose control in type 2 diabetes. BMJ 2008;336:458-459
CrossRef | Web of Science | Medline23
Gerstein H ,Mann J ,Yi Q , et al. Albuminuria and risk of CV events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001;286:421-426
CrossRef | Web of Science | Medline24
Go AS ,Chertow GM ,Fan D ,McCulloch CE ,Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305
Full Text | Web of Science | Medline25
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
CrossRef | Web of Science | Medline26
Keech AC ,Mitchell P ,Summanen PA , et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-1697
CrossRef | Web of Science | Medline27
Stolk RP ,Vingerling JR ,Cruickshank JK , et al. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp Clin Trials 2007;28:6-17
CrossRef | Web of Science | Medline28
Abraira C ,Duckworth W ,McCarren M , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17:314-322
CrossRef | Web of Science | Medline29
Fava D ,Cassone-Faldetta M ,Laurenti O ,De Luca O ,Ghiselli A ,De Mattia G . Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet Med 2002;19:752-757
CrossRef | Web of Science | Medline30
Belcher G ,Lambert C ,Goh KL ,Edwards G ,Valbuena M . Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004;58:833-837
CrossRef | Web of Science | Medline31
Wascher TC ,Boes U . Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. Clin Physiol Funct Imaging 2005;25:40-46
CrossRef | Web of Science | Medline32
Gaede P ,Lund-Andersen H ,Parving H-H ,Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
Full Text | Web of Science | Medline33
Turnbull F ,Neal B ,Algert C , et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prespectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-1419
CrossRef | Web of Science | Medline34
Baigent C ,Keech A ,Kearney PM , et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278[Erratum, Lancet 2005;366:1358.]
CrossRef | Web of Science | Medline
- Citing Articles (733)
Citing Articles
1
Yaron Bar Dayan, Jose Mario F. de Oliveira, Dean Jenkins, Sabreena Malik, Rakesh Biswas. (2013) Creating Secondary Learning Resources from Web Based Conversational Learning Around ‘Rational Usage of Medicines’ in Diabetes. International Journal of User-Driven Healthcare 1:4, 77-84
CrossRef2
Rikki M. Tanner, Todd M. Brown, Paul Muntner. (2012) Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease. Current Hypertension Reports
CrossRef3
Kenichi Matsuura, Yutaka Mori, Asuka Nakamura, Junichi Yokoyama, Kazunori Utsunomiya. (2012) Effect of Miglitol as an Add-On to Bolus Insulin on Postprandial Glycemic Excursions in Type 2 Diabetes Patients Assessed by Continuous Glucose Monitoring. Diabetes Technology & Therapeutics120208094748008
CrossRef4
Sophia Zoungas, John Chalmers. (2012) Diabetes: Glycemic control and outcomes in people with diabetes and CKD. Nature Reviews Nephrology
CrossRef5
C. R. Mikus, D. J. Oberlin, J. Libla, L. J. Boyle, J. P. Thyfault. (2012) Glycaemic control is improved by 7 days of aerobic exercise training in patients with type 2 diabetes. Diabetologia
CrossRef6
Ronald Pyram, Abhishek Kansara, Mary Ann Banerji, Lisel Loney-Hutchinson. (2012) Chronic kidney disease and diabetes. Maturitas 71:2, 94-103
CrossRef7
Katherine Esposito, Dario Giugliano. (2012) Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opinion on Biological Therapy 12:2, 209-221
CrossRef8
Q. Zhang, S. Rajagopalan, E. Marrett, M. J. Davies, L. Radican, S. S. Engel. (2012) Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. Diabetes, Obesity and Metabolism 14:2, 149-154
CrossRef9
Soo Lim, Martin K. Rutter. (2012) Unfavorable Effects of Intensive Glucose Lowering on Mortality: Lessons from the 5-Year Follow-up of the ACCORD Trial. Current Cardiovascular Risk Reports 6:1, 1-3
CrossRef10
P. S. Sharp, A. Brown. (2012) Glycaemic control in patients with diabetes at the point of referral for a second opinion. Diabetic Medicine 29:2, 285-286
CrossRef11
J. L. Oke, R. J. Stevens, K. Gaitskell, A. J. Farmer. (2012) Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model. Diabetic Medicine 29:2, 266-271
CrossRef12
Yong-Jun Wang, Su-Ming Zhang, Liqun Zhang, Chun-Xue Wang. (2012) Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 2010. CNS Neuroscience & Therapeutics 18:2, 93-101
CrossRef13
G. S. Hillis, M. Woodward, A. Rodgers, C. K. Chow, Q. Li, S. Zoungas, A. Patel, R. Webster, G. D. Batty, T. Ninomiya, G. Mancia, N. R. Poulter, J. Chalmers. (2012) Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia
CrossRef14
M. Rahman, R. K. Simmons, S. H. Hennings, N. J. Wareham, S. J. Griffin. (2012) How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia
CrossRef15
Bernhard Ludvik, Guntram Schernthaner. (2012) Diabetes Care Austria 2009: Register an allgemeinmedizinischen Ordinationen für PatientInnen mit Typ 2 Diabetes mellitus in Österreich. Wiener klinische Wochenschrift
CrossRef16
B. Detournay, D. Simon, P.-J. Guillausseau, D. Joly, B. Verges, C. Attali, O. Clement, Y. Briand, O. Delaitre. (2012) Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes & Metabolism
CrossRef17
Mohammad Shamsul Ola, Mohd Imtiaz Nawaz, M. Mairaj Siddiquei, Saleh Al-Amro, Ahmed M. Abu El-Asrar. (2012) Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Journal of Diabetes and its Complications
CrossRef18
Clement Lo, Sophia Zoungas. (2012) Reducing renal failure: how low do glucose levels need to go?. Diabetes Management 2:1, 25-32
CrossRef19
A. Avogaro. (2012) Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes, Obesity and Metabolism 14, 14-19
CrossRef20
Toyoaki Murohara. (2012) Dipeptidyl Peptidase-4 Inhibitor. Journal of the American College of Cardiology 59:3, 277-279
CrossRef21
S. Colagiuri. (2012) Optimal management of type 2 diabetes: the evidence. Diabetes, Obesity and Metabolism 14, 3-8
CrossRef22
Emily S. Brouwer, Suzanne L. West, Marianne Kluckman, Dennis Wallace, Andrew L. Masica, Edward Ewen, Rustam Kudyakov, Dunlei Cheng, James Bowen, Neil S. Fleming. (2012) Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef23
William T. Cefalu. (2012) Evolving Treatment Strategies for the Management of Type 2 Diabetes. The American Journal of the Medical Sciences 343:1, 21-26
CrossRef24
Karthik Balasubramaniam, Girish N. Viswanathan, Sally M. Marshall, Azfar G. Zaman. (2012) Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice 2012, 1-18
CrossRef25
Mei-Fang Zhong, Wei-Li Shen, Masaki Tabuchi, Kyoko Nakamura, Yi-Chen Chen, Cong-Zhen Qiao, Jin He, Jie Yang, Chuan Zhang, Zdravko Kamenov, Hideaki Higashino, Hong Chen. (2012) Differential Changes of Aorta and Carotid Vasodilation in Type 2 Diabetic GK and OLETF Rats: Paradoxical Roles of Hyperglycemia and Insulin. Experimental Diabetes Research 2012, 1-16
CrossRef26
R. A. DeFronzo, J. A. Davidson, S. Del Prato. (2012) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes, Obesity and Metabolism 14:1, 5-14
CrossRef27
Chaoyang Li, Earl S. Ford, Guixiang Zhao, James Tsai, Lina S. Balluz, Wayne H. Giles. (2012) Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995–2007. Journal of Diabetes and its Complications
CrossRef28
P. Hamet. (2012) What matters in ADVANCE and ADVANCE-ON. Diabetes, Obesity and Metabolism 14, 20-29
CrossRef29
A. Prescott, J.E. Bailey, K.J. Kelly, T. Munyombwe, A. Gray, L.K.M. Summers. (2012) The effectiveness and cost of single and multi-factorial cardiovascular risk factor modification to guideline targets in type 2 diabetes. Primary Care Diabetes
CrossRef30
Simona Primožič, Rok Tavčar, Magdalena Avbelj, Mojca Zvezdana Dernovšek, Maja Ravnik Oblak. (2012) Specific cognitive abilities are associated with diabetes self-management behavior among patients with type 2 diabetes. Diabetes Research and Clinical Practice 95:1, 48-54
CrossRef31
Jose Luis Gorriz, Alberto Martinez-Castelao. (2012) Proteinuria: detection and role in native renal disease progression. Transplantation Reviews 26:1, 3-13
CrossRef32
Nikhil Tandon, Mohammed K. Ali, K.M. Venkat Narayan. (2012) Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. American Journal Cardiovascular Drugs1
CrossRef33
Ofelia Llamazares Iglesias, Julia Sastre Marcos, Virginia Peña Cortés, Alessandra Luque Pazos, Bárbara Cánovas Gaillemin, Almudena Vicente Delgado, Amparo Marco Martínez, José López López. (2012) Control metabólico y de factores de riesgo cardiovascular en una cohorte de pacientes con diabetes mellitus. Resultados a los 4 años. Endocrinología y Nutrición
CrossRef34
Min Goo Lee, Myung Ho Jeong, Dong Han Kim, Ki Hong Lee, Keun Ho Park, Doo Sun Sim, Hyun Ju Yoon, Nam Sik Yoon, Kye Hun Kim, Hyoung Wook Park, Young Joon Hong, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2012) Predictive value of glycosylated hemoglobin for mortality of patients with acute myocardial infarction undergoing percutaneous coronary intervention. International Journal of Cardiology
CrossRef35
Rashed Al Bannay, Aysha Husain. (2012) Hypertensive crisis: Comparison between diabetics and non-diabetics. International Journal of Cardiology 154:2, 198-200
CrossRef36
S. van Dieren, S. Czernichow, J. Chalmers, A.P. Kengne, B.E. de Galan, N. Poulter, M. Woodward, J.W.J. Beulens, D.E. Grobbee, Y.T. van der Schouw, S. Zoungas. (2012) Weight changes and their predictors amongst 11,140 patients with type 2 diabetes in the ADVANCE trial. Diabetes, Obesity and Metabolismno-no
CrossRef37
Juan José Gorgojo Martínez. (2012) Glucocentricity or adipocentricity: A critical view of consensus and clinical guidelines for the treatment of type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition)
CrossRef38
, S. Zoungas, J. Chalmers, T. Ninomiya, Q. Li, M. E. Cooper, S. Colagiuri, G. Fulcher, B. E. Galan, S. Harrap, P. Hamet, S. Heller, S. MacMahon, M. Marre, N. Poulter, F. Travert, A. Patel, B. Neal, M. Woodward. (2011) Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia
CrossRef39
2011. Complications Associated with Diabetes. , 201-249.
CrossRef40
2011. Type 2 Diabetes in Adults. , 77-137.
CrossRef41
Jeffrey M Turner, Carolyn Bauer, Matthew K Abramowitz, Michal L Melamed, Thomas H Hostetter. (2011) Treatment of chronic kidney disease. Kidney International
CrossRef42
Neda Laiteerapong, Elbert S. Huang, Marshall H. Chin. (2011) Prioritization of care in adults with diabetes and comorbidity. Annals of the New York Academy of Sciences 1243:1, 69-87
CrossRef43
Joo-Pin Foo, Christos S. Mantzoros. (2011) The quest for the perfect biomarker of long-term glycemia: new studies, new trials and tribulations. Metabolism 60:12, 1651-1654
CrossRef44
Juan José Gorgojo Martínez. (2011) Glucocentrismo o adipocentrismo: una visión crítica de los consensos y guías clínicas para el tratamiento de la diabetes mellitus tipo 2. Endocrinología y Nutrición 58:10, 541-549
CrossRef45
Chih-Chieh Chou, Wei-Liang Chen, Tung-Wei Kao, Yaw-Wen Chang, Ching-Hui Loh, Chung-Ching Wang. (2011) Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese Population. Clinical Therapeutics 33:12, 1904-1913
CrossRef46
D. Kerr, H. Partridge, J. Knott, P. W. Thomas. (2011) HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabetic Medicine 28:12, 1520-1524
CrossRef47
V. Koivisto, S. Cleall, A. E. Pontiroli, D. Giugliano. (2011) Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes, Obesity and Metabolism 13:12, 1149-1157
CrossRef48
Ravichandran Ramasamy, Shi Fang Yan, Ann Marie Schmidt. (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Annals of the New York Academy of Sciences 1243:1, 88-102
CrossRef49
F. E. Vos, J. B. Schollum, R. J. Walker. (2011) Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease. NDT Plus 4:6, 368-375
CrossRef50
S. Zoungas, M. Lui, P. G. Kerr, H. J. Teede, J. J. McNeil, B. P. McGrath, K. R. Polkinghorne. (2011) Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial. Internal Medicine Journal 41:12, 825-832
CrossRef51
K. L. Rensing, A. Q. Reuwer, B. J. Arsenault, J. H. von der Thüsen, J. B. L. Hoekstra, J. J. P. Kastelein, Th. B. Twickler. (2011) Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. Diabetes, Obesity and Metabolism 13:12, 1073-1087
CrossRef52
Zachary Bloomgarden, Yehuda Handelsman, Daniel Einhorn. (2011) Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. Journal of Diabetes 3:4, 257-260
CrossRef53
Anna Maria Buehler, Alexandre Biasi Cavalcanti, Otavio Berwanger, Mabel Figueiro, Lígia Nasi Laranjeira, Ana Denise Zazula, Bruno Kioshi, Diogo G. Bugano, Eliana Santucci, Grazielle Sbruzzi, Helio Penna Guimaraes, Vitor Oliveira Carvalho, Silvana Auxiliadora Bordin. (2011) Effect of Tight Blood Glucose Control Versus Conventional Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. Cardiovascular Therapeuticsno-no
CrossRef54
M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, I. Gause-Nilsson, K-M. Schützer. (2011) Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. International Journal of Clinical Practice 65:12, 1230-1239
CrossRef55
Pierre-Jean Guillausseau. (2011) Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate is Not yet Closed. Current Diabetes Reports 11:6, 461-462
CrossRef56
L. Cai, Y. Cai, Z. J. Lu, Y. Zhang, P. Liu. (2011) The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of Clinical Pharmacy and Therapeuticsno-no
CrossRef57
Clare Bradley, Pedro de Pablos-Velasco, Klaus G. Parhofer, Eveline Eschwège, Linda Gönder-Frederick, Dominique Simon. (2011) PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus—Study design. Primary Care Diabetes 5:4, 231-239
CrossRef58
Denise G. Feil, Mangala Rajan, Orysya Soroka, Chin-Lin Tseng, Donald R. Miller, Leonard M. Pogach. (2011) Risk of Hypoglycemia in Older Veterans with Dementia and Cognitive Impairment: Implications for Practice and Policy. Journal of the American Geriatrics Society 59:12, 2263-2272
CrossRef59
T. J. Quinn, J. Dawson, M. R. Walters. (2011) Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control. Cardiovascular Therapeutics 29:6, e31-e42
CrossRef60
B. Vergès, A. Avignon, F. Bonnet, B. Catargi, S. Cattan, E. Cosson, G. Ducrocq, M. Elbaz, A. Fredenrich, P. Gourdy, P. Henry, O. Lairez, A.M. Leguerrier, C. Monpère, P. Moulin, B. Vergès-Patois, R. Roussel, G. Steg, P. Valensi. (2011) Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes & Metabolism
CrossRef61
Nicole Soranzo. (2011) Genetic Determinants of Variability in Glycated Hemoglobin (HbA1c) in Humans: Review of Recent Progress and Prospects for Use in Diabetes Care. Current Diabetes Reports 11:6, 562-569
CrossRef62
Susan R. Kirsh, David C. Aron. (2011) Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. Drugs & Aging 28:12, 945-960
CrossRef63
N. Diehm, J. Schmidli, C. Setacci, J.-B. Ricco, G. de Donato, F. Becker, H. Robert-Ebadi, P. Cao, H.H. Eckstein, P. De Rango, M. Teraa, F.L. Moll, F. Dick, A.H. Davies, M. Lepäntalo, J. Apelqvist. (2011) Chapter III: Management of Cardiovascular Risk Factors and Medical Therapy. European Journal of Vascular and Endovascular Surgery 42, S33-S42
CrossRef64
J.M. Cabezas Agrícola, F.F. Casanueva. (2011) Tratamiento de la hiperglucemia en la diabetes mellitus tipo 2: Hacia un tratamiento individualizado. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6230-6239
CrossRef65
Shogo Asano, Atsushi Suzuki, Junnichi Ishii, Sahoko Sekiguchi-Ueda, Megumi Shibata, Yasumasa Yoshino, Kazuhiro Nakamura, Yasukazu Akiyama, Fumihiko Kitagawa, Toshiaki Sakuishi, Takashi Fujita, Mitsuyasu Itoh. (2011) Use of a new high-sensitivity assay for cardiac troponin T to stratify the risk of cardiovascular disease in outpatients with type-2 diabetes. Diabetology International
CrossRef66
F. C. Sasso, P. Chiodini, O. Carbonara, L. De Nicola, G. Conte, T. Salvatore, R. Nasti, R. Marfella, C. Gallo, S. Signoriello, R. Torella, R. Minutolo, . (2011) High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. Nephrology Dialysis Transplantation
CrossRef67
Jennifer A. Colby, Fei Wang, Jyoti Chhabra, Rafael Pérez-Escamilla. (2011) Predictors of Medication Adherence in an Urban Latino Community with Healthcare Disparities. Journal of Immigrant and Minority Health
CrossRef68
N. Altemtam, J. Russell, M. El Nahas. (2011) A study of the natural history of diabetic kidney disease (DKD). Nephrology Dialysis Transplantation
CrossRef69
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Ph. Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Deborah L. Price, Roland Chen, Jacob Udell, Itamar Raz. (2011) The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal 162:5, 818-825.e6
CrossRef70
Philip E. Cryer. (2011) Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications. The American Journal of Medicine 124:11, 993-996
CrossRef71
Davide Castagno, Jonathan Baird-Gunning, Pardeep S. Jhund, Giuseppe Biondi-Zoccai, Michael R. MacDonald, Mark C. Petrie, Fiorenzo Gaita, John J.V. McMurray. (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal 162:5, 938-948.e2
CrossRef72
Laura Boucai, William N. Southern, Joel Zonszein. (2011) Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to Comorbidities. The American Journal of Medicine 124:11, 1028-1035
CrossRef73
Eli N. Deal, Aiqun Liu, Laura L. Wise, Kathy A. Honick, Garry S. Tobin. (2011) Inpatient insulin orders: Are patients getting what is prescribed?. Journal of Hospital Medicine 6:9, 526-529
CrossRef74
J. Tafel, M. Buerstell, C. Leippert, E. Benack, A. Stelling, C. Jaeger. (2011) Diabetesmanagement in der Klinik. Der Diabetologe 7:7, 472-479
CrossRef75
Richard S. Beaser, Eyiuche Okeke, James Neighbours, Julie Brown, Katie Ronk, Walter W. Wolyniec. (2011) Coordinated Primary and Specialty Care for Type 2 Diabetes Mellitus, Guidelines, and Systems: An Educational Needs Assessment. Endocrine Practice 17:6, 880-890
CrossRef76
Antonio Pérez, Josep Franch, Aleix Cases, José Ramón González Juanatey, Pedro Conthe, Eva Gimeno, Arantxa Matali. (2011) Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES. Medicina Clínica
CrossRef77
Jing Tian, Yanling Wen, Li Yan, Hua Cheng, Haiyun Yang, Jingfeng Wang, Hani Kozman, Daniel Villarreal, Kan Liu. (2011) Vascular Endothelial Dysfunction in Patients with Newly Diagnosed Type 2 Diabetes and Effects of 2-year and 5-year Multifactorial Intervention. Echocardiography 28:10, 1133-1140
CrossRef78
Niki Katsiki, Nikolaos Papanas, Dimitri P. Mikhailidis, Vivian A. Fonseca. (2011) Glycated hemoglobin A 1c (HbA 1c ) and diabetes: a new era?. Current Medical Research and Opinion 27:S3, 7-11
CrossRef79
Brian J. Quilliam, Jason C. Simeone, A. Burak Ozbay. (2011) Risk Factors for Hypoglycemia-Related Hospitalization in Patients With Type 2 Diabetes: A Nested Case–Control Study. Clinical Therapeutics 33:11, 1781-1791
CrossRef80
Janice M. Scheufler, Maryjo Prince-Paul. (2011) The Diabetic Hospice Patient. Journal of Hospice & Palliative Nursing 13:6, 356-365
CrossRef81
P Lee, A-P Kengne, J R Greenfield, R O Day, J Chalmers, K K Y Ho. (2011) Metabolic sequelae of β-blocker therapy: weighing in on the obesity epidemic?. International Journal of Obesity 35:11, 1395-1403
CrossRef82
William C. Duckworth, Carlos Abraira, Thomas E. Moritz, Stephen N. Davis, Nicholas Emanuele, Steven Goldman, Rodney Hayward, Grant D. Huang, Jennifer B. Marks, Peter D. Reaven, Domenic J. Reda, Stuart R. Warren, Franklin J. Zieve. (2011) The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes and its Complications 25:6, 355-361
CrossRef83
Alan J. Sinclair, Giuseppe Paolisso, Marta Castro, Isabelle Bourdel-Marchasson, Roger Gadsby, Leocadio Rodriguez Mañas. (2011) European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary. Diabetes & Metabolism 37, S27-S38
CrossRef84
David Sullivan, Peta Forder, John Simes, Malcolm Whiting, Leonard Kritharides, Alistair Merrifield, Mark Donoghoe, Peter G. Colman, Neil Graham, Hannu Haapamäki, Anthony Keech. (2011) Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Research and Clinical Practice 94:2, 284-290
CrossRef85
Louis Monnier, Claude Colette, David Owens. (2011) The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts?. Diabetes Research and Clinical Practice
CrossRef86
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2011) Clinical Update on Nursing Home Medicine: 2011. Journal of the American Medical Directors Association 12:9, 615-626.e6
CrossRef87
Alexandria M. Dailey, Jennifer A. Gibert, Lisa R. Tannock. (2011) Durability of glycemic control using U-500 insulin. Diabetes Research and Clinical Practice
CrossRef88
Emaad M. Abdel-Rahman, Lawand Saadulla, W. Brian Reeves, Alaa S. Awad. (2011) Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. Journal of General Internal Medicine
CrossRef89
Cheow Peng Ooi, Seng Cheong Loke, Cheow Peng Ooi. 2011. Colesevelam for type 2 diabetes mellitus. .
CrossRef90
Bruce Barrett. (2011) Evidence, Values, Guidelines and Rational Decision-making. Journal of General Internal Medicine
CrossRef91
MW Savage, I Malik, CN Dang. (2011) The case for basal analogue insulins as first-line insulins: back to the future?. Practical Diabetes 28:8, 329-330
CrossRef92
G.-D. Batty, Q. Li, R. Huxley, S. Zoungas, B.-A. Taylor, B. Neal, B. de Galan, M. Woodward, S.-B. Harrap, S. Colagiuri, A. Patel, J. Chalmers. (2011) Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry
CrossRef93
William B. White, George L. Bakris, Richard M. Bergenstal, Christopher P. Cannon, William C. Cushman, Penny Fleck, Simon Heller, Cyrus Mehta, Steven E. Nissen, Alfonso Perez, Craig Wilson, Faiez Zannad. (2011) EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). American Heart Journal 162:4, 620-626.e1
CrossRef94
Masaharu Ishihara, Ichiro Inoue, Takuji Kawagoe, Yuji Shimatani, Satoshi Kurisu, Yasuharu Nakama, Eisuke Kagawa, Kazuoki Dai, Takayuki Ootani, Hiroki Ikenaga, Yoshimasa Morimoto, Kentarou Ejiri, Nozomu Oda. (2011) Glucometabolic responses during Glucose Tolerance Test: A comparison between known diabetes and newly detected diabetes after acute myocardial infarction. International Journal of Cardiology 152:1, 78-82
CrossRef95
A. Chaudhuri, P. Dandona. (2011) Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, Obesity and Metabolism 13:10, 869-879
CrossRef96
Kyaw Soe, Alan Sacerdote, Jocelyn Karam, Gül Bahtiyar. (2011) Management of type 2 diabetes mellitus in the elderly. Maturitas 70:2, 151-159
CrossRef97
Yoshifumi Saisho, Kumiko Tanaka, Takayuki Abe, Akira Shimada, Toshihide Kawai, Hiroshi Itoh. (2011) Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetology International 2:3, 146-153
CrossRef98
Vasant Hirani. (2011) Relationship Between Vitamin D and Hyperglycemia in Older People From a Nationally Representative Population Survey. Journal of the American Geriatrics Society 59:10, 1786-1792
CrossRef99
J.J. Gagliardino, P. Aschner, S.H. Baik, J. Chan, J.M. Chantelot, H. Ilkova, A. Ramachandran. (2011) Patients’ education, and its impact on care outcomes, resource consumption and working conditions: Data from the International Diabetes Management Practices Study (IDMPS). Diabetes & Metabolism
CrossRef100
J. I. Vidal Pardo, T. R. Pérez Castro, X. L. López Álvarez, F. J. García Soidán, M. I. Santiago Pérez, J. Muñiz. (2011) Quality of care of patients with type-2 diabetes in Galicia (NW Spain) [OBTEDIGA project]. International Journal of Clinical Practice 65:10, 1067-1075
CrossRef101
Gregory A. Nichols, Suma Vupputuri, A. Gabriela Rosales. (2011) Change in High-Density Lipoprotein Cholesterol and Risk of Subsequent Hospitalization for Coronary Artery Disease or Stroke Among Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology 108:8, 1124-1128
CrossRef102
Ulf G. Bronas, Diane Treat-Jacobson. (2011) Peripheral Artery Disease in the Elderly: Prevalence, Clinical Implications, and Therapy. Current Cardiovascular Risk Reports 5:5, 457-466
CrossRef103
Kwame S. Amankwah. (2011) Is Hemoglobin A1c an Adequate Marker for Disease Severity and Outcome in Limb Threatening Ischemia?. Journal of Surgical Research
CrossRef104
B. R. Peskin, A. V. Shcheprov, K. S. Boye, S. Bruce, D. G. Maggs, J. A. Gaebler. (2011) Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes, Obesity and Metabolism 13:10, 921-927
CrossRef105
, S. Gudbjörnsdottir, B. Eliasson, K. Eeg-Olofsson, B. Zethelius, J. Cederholm. (2011) Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia 54:10, 2544-2551
CrossRef106
Shinji Kume, Takashi Uzu, Chieko Takagi, Morihiro Kondo, Tomoko Okabe, Shin-ichi Araki, Keiji Isshiki, Naoko Takeda, Keiko Kondo, Masakazu Haneda, Daisuke Koya, Yoshihiko Nishio, Atsunori Kashiwagi, Hiroshi Maegawa. (2011) Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis. Journal of Diabetes Investigationno-no
CrossRef107
B. Ahrén. (2011) The future of incretin-based therapy: novel avenues-novel targets. Diabetes, Obesity and Metabolism 13, 158-166
CrossRef108
Richard J. MacIsaac, George Jerums. (2011) Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes. Heart, Lung and Circulation 20:10, 647-654
CrossRef109
Michael Pfeiffer, Rüdiger Bauer, Peter P. Nawroth. (2011) The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies. Langenbeck's Archives of Surgery 396:7, 941-947
CrossRef110
Ross Milne, Seymour Brownstein. (2011) Advanced glycation end products and diabetic retinopathy. Amino Acids
CrossRef111
M. K. Rutter, R. W. Nesto. (2011) Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. European Heart Journal 32:18, 2247-2255
CrossRef112
B. Fuentes, J. Gállego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor, M. Alonso de Leciñana, J. Álvarez-Sabin, J. Arenillas, S. Calleja, I. Casado, M. Castellanos, J. Castillo, A. Dávalos, F. Díaz-Otero, J.A. Egido, J.C. López-Fernández, M. Freijo, A. García Pastor, F. Gilo, P. Irimia, J. Maestre, J. Masjuan, J. Martí-Fábregas, P. Martínez-Sánchez, E. Martínez-Vila, C. Molina, F. Nombela, M. Ribó, M. Rodríguez-Yañez, F. Rubio, J. Serena, P. Simal, J. Vivancos. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida. Neurología
CrossRef113
Geremia B. Bolli, Larry C. Deeb, Satish K. Garg, John L. Leahy, Roger S. Mazze, David R. Owens, Matthew C. Riddle, Phil Southerland, Ellie S. Strock. (2011) International Forum for the Advancement of Diabetes Research and Care, April 29–30, 2011, Athens, Greece. Diabetes Technology & Therapeutics 13:9, 967-979
CrossRef114
F. Bonnet, E. Gauthier, H. Gin, S. Hadjadj, J.-M. Halimi, T. Hannedouche, V. Rigalleau, D. Romand, R. Roussel, P. Zaoui. (2011) Expert consensus on management of diabetic patients with impairment of renal function. Diabetes & Metabolism 37, S1-S25
CrossRef115
Jamie C. Barner. (2011) Adherence to Oral Antidiabetic Agents with Pioglitazone and Metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy. Clinical Therapeutics 33:9, 1281-1288
CrossRef116
Scott V. Joy, Jeffrey S. Freeman, James R. LaSalle. (2011) Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. Osteopathic Family Physician 3:5, 217-236
CrossRef117
Evelyn P. Davila, Hermes Florez, Mary Jo Trepka, Lora E. Fleming, Theophile Niyonsenga, David J. Lee, Jai Parkash. (2011) Strict glycemic control and mortality risk among US adults with type 2 diabetes. Journal of Diabetes and its Complications 25:5, 289-291
CrossRef118
Vanita R. Aroda, Robert Ratner. (2011) The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews 27:6, 528-542
CrossRef119
Luca Busetto, Paolo Sbraccia, Lucia Frittitta, Antonio E. Pontiroli. (2011) The Growing Role of Bariatric Surgery in the Management of Type 2 Diabetes: Evidences and Open Questions. Obesity Surgery 21:9, 1451-1457
CrossRef120
Mikko T. Honkasalo, Outi M. Elonheimo, Timo Sane. (2011) Severe hypoglycaemia in drug-treated diabetic patients needs attention: A population-based study. Scandinavian Journal of Primary Health Care 29:3, 165-170
CrossRef121
Yannis S. Guerra, Evelyn A. Lacuesta, Rodger Yrastorza, Jadwiga Miernik, Niva Shakya, Leon Fogelfeld. (2011) Insulin Injections in Relation to Meals in the Hospital Medicine Ward: Comparison of 2 Protocols. Endocrine Practice 17:5, 737-746
CrossRef122
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2011) Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. Clínica e Investigación en Arteriosclerosis 23:5, 230-239
CrossRef123
Michel Marre, Alfred Penfornis. (2011) GLP-1 receptor agonists today. Diabetes Research and Clinical Practice 93:3, 317-327
CrossRef124
D. R. Webb, L. J. Gray, K. Khunti, B. Srinivasan, N. Taub, S. Campbell, J. Barnett, A. Farooqi, J. B. Echouffo-Tcheugui, S. J. Griffin, N. J. Wareham, M. J. Davies. (2011) Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia 54:9, 2237-2246
CrossRef125
Joseph G. Ibrahim, Ming-Hui Chen, H. Amy Xia, Thomas Liu. (2011) Bayesian Meta-Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Biometricsno-no
CrossRef126
Sudha Vidyasagar, Nataraj, Muralidhar Varma, C. K. Prashanth, Yeshwanth Rao, B. Kavitha. (2011) A critical analysis of the concept of secondary Oral Hypoglycemic Agent (OHA) failure in type 2 diabetes at a tertiary care hospital. International Journal of Diabetes in Developing Countries 31:3, 161-165
CrossRef127
John J. Ricotta, Ali AbuRahma, Enrico Ascher, Mark Eskandari, Peter Faries, Brajesh K. Lal. (2011) Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery 54:3, e1-e31
CrossRef128
Devasmita Choudhury, Moshe Levi. (2011) Kidney aging—inevitable or preventable?. Nature Reviews Nephrology 7:12, 706-717
CrossRef129
Yehuda Handelsman, Paul S. Jellinger. (2011) Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 13:8, 613-620
CrossRef130
Daisuke Koya, Shin-ichi Araki, Masakazu Haneda. (2011) Therapeutic management of diabetic kidney disease. Journal of Diabetes Investigation 2:4, 248-254
CrossRef131
George Stamataros, Stephen H Schneider. (2011) Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:12, 1967-1973
CrossRef132
Michael H. Davidson. (2011) Cardiovascular Effects of Glucagonlike peptide–1 Agonists. The American Journal of Cardiology 108:3, 33B-41B
CrossRef133
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef134
Sherita Hill Golden. (2011) Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications. The American Journal of Cardiology 108:3, 59B-67B
CrossRef135
T. K. Schramm, G. H. Gislason, A. Vaag, J. N. Rasmussen, F. Folke, M. L. Hansen, E. L. Fosbol, L. Kober, M. L. Norgaard, M. Madsen, P. R. Hansen, C. Torp-Pedersen. (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European Heart Journal 32:15, 1900-1908
CrossRef136
Jorge Plutzky. (2011) Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. The American Journal of Cardiology 108:3, 25B-32B
CrossRef137
H. Sourij, I. Schmoelzer, A. de Campo, N. J. Tripolt, T. Stojakovic, H. Scharnagl, E. Kettler-Schmut, T. Forst, T. C. Wascher. (2011) Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes. European Journal of Endocrinology 165:2, 269-274
CrossRef138
Vivian A. Fonseca. (2011) Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus. The American Journal of Cardiology 108:3, 52B-58B
CrossRef139
M. O. Gore, D. K. McGuire. (2011) Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. European Heart Journal 32:15, 1832-1834
CrossRef140
Ralph A. DeFronzo, Muhammad Abdul-Ghani. (2011) Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. The American Journal of Cardiology 108:3, 3B-24B
CrossRef141
E. Ferrannini, D. J. Betteridge, J. A. Dormandy, B. Charbonnel, R. G. Wilcox, R. Spanheimer, E. Erdmann, R. A. DeFronzo, M. Laakso. (2011) High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes, Obesity and Metabolism 13:8, 759-764
CrossRef142
Junya Aoki, Ken Uchino. (2011) Treatment of Risk Factors to Prevent Stroke. Neurotherapeutics 8:3, 463-474
CrossRef143
Gina J. Ryan, Karla T. Foster, Lynetta Johnson Jobe. (2011) Review of the Therapeutic Uses of Liraglutide. Clinical Therapeutics 33:7, 793-811
CrossRef144
Wan-gen Li, Xin-lian He, Tong Zhang, Guang-da Xiang, Jian-min Ran, Cheng Peng, Hong Zhang. (2011) Hemoglobin A1c proportion, mortality rate, and risk factors for death in diabetic patients with severe hypoglycemia: A multicenter retrospective survey over ten years. Diabetes Research and Clinical Practice 93:1, 17-20
CrossRef145
Garth J.S. Cooper. (2011) Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimerʼs Disease. Drugs 71:10, 1281-1320
CrossRef146
Mohammad H. Murad, Nilay D. Shah, Holly K. Van Houten, Jeanette Y. Ziegenfuss, James R. Deming, Timothy J. Beebe, Steven A. Smith, Gordon H. Guyatt, Victor M. Montori. (2011) Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. Journal of Clinical Epidemiology 64:7, 743-748
CrossRef147
Ryotaro Bouchi, Tetsuya Babazono, Michino Mugishima, Naoshi Yoshida, Izumi Nyumura, Kiwako Toya, Toshihide Hayashi, Ko Hanai, Nobue Tanaka, Akiko Ishii, Yasuhiko Iwamoto. (2011) Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. Journal of Diabetes Investigationno-no
CrossRef148
Kerstin Kempf, Reiner Füth, Wilfried Dinh, Lars Bansemir, Till Köhler, Alexander Bufe, Thomas Scheffold, Eberhard Standl, Stephan Martin, Mark Lankisch. (2011) Screening for overt diabetes by oral glucose tolerance test: Stratification by fasting blood glucose and patients' age improve practicability of guidelines in cardiological routine. International Journal of Cardiology 150:2, 201-205
CrossRef149
Tuomas Kerola, Raimo Kettunen, Tuomo Nieminen. (2011) The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology 150:2, 123-129
CrossRef150
W. L. Jin, K. Azuma, T. Mita, H. Goto, A. Kanazawa, T. Shimizu, F. Ikeda, Y. Fujitani, T. Hirose, R. Kawamori, H. Watada. (2011) Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. Diabetologia 54:7, 1921-1929
CrossRef151
Pedro Romero-Aroca. (2011) Factores de riesgo y efecto de los fármacos administrados por vía sistémica sobre la retinopatía diabética. Medicina Clínica 137:4, 161-162
CrossRef152
G. Stefansdottir, S. Zoungas, J. Chalmers, A. P. Kengne, M. J. Knol, H. G. M. Leufkens, A. Patel, M. Woodward, D. E. Grobbee, M. L. Bruin. (2011) Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 54:7, 1608-1614
CrossRef153
B. T. Corley, C. Davenport, L. Delaney, M. Hatunic, D. Smith. (2011) Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse. Diabetic Medicine 28:7, 876-879
CrossRef154
J. B. Echouffo-Tcheugui, M. K. Ali, S. J. Griffin, K. M. V. Narayan. (2011) Screening for Type 2 Diabetes and Dysglycemia. Epidemiologic Reviews 33:1, 63-87
CrossRef155
Sanjay Gandhi, Ido Weinberg, Ronan Margey, Michael R. Jaff. (2011) Comprehensive Medical Management of Peripheral Arterial Disease. Progress in Cardiovascular Diseases 54:1, 2-13
CrossRef156
Maíra Viégas, Christiane Costa, Arthur Lopes, Luiz Griz, Maria Antonieta Medeiro, Francisco Bandeira. (2011) Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. Journal of Diabetes and its Complications 25:4, 216-221
CrossRef157
Mark Thomas Hayes, Lynette Anne Hunt, Jonathan Foo, Yulia Tychinskaya, Richard Strawson Stubbs. (2011) A Model for Predicting the Resolution of Type 2 Diabetes in Severely Obese Subjects Following Roux-en Y Gastric Bypass Surgery. Obesity Surgery 21:7, 910-916
CrossRef158
S. H. Wild. (2011) Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations. Diabetologia 54:7, 1589-1592
CrossRef159
Mark WI Webster. (2011) Clinical practice and implications of recent diabetes trials. Current Opinion in Cardiology 26:4, 288-293
CrossRef160
Alice YY Cheng, Lawrence A Leiter. (2011) ACCORD microvascular and Eye substudy: should the results change our practice?. Diabetes Management 1:4, 389-396
CrossRef161
R.P. Donahue, J.M. Dorn, S. Stranges, M. Swanson, K. Hovey, M. Trevisan. (2011) Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: Evidence of a sex difference? The Western New York experience. Nutrition, Metabolism and Cardiovascular Diseases 21:7, 504-511
CrossRef162
S. W. Oh, Y. C. Kim, H. S. Koo, D. C. Jin, K. Y. Na, D. W. Chae, S. Kim, H. J. Chin. (2011) Glycated haemoglobin and the incidence of end-stage renal disease in diabetics. Nephrology Dialysis Transplantation 26:7, 2238-2244
CrossRef163
Charlie Tomson, Pippa Bailey. (2011) Management of chronic kidney disease. Medicine 39:7, 407-413
CrossRef164
Carla K Miller, Amy Headings, Mark Peyrot, Haikady Nagaraja. (2011) A behavioural intervention incorporating specific glycaemic index goals improves dietary quality, weight control and glycaemic control in adults with type 2 diabetes. Public Health Nutrition 14:07, 1303-1311
CrossRef165
A. Zimmermann, H. Berger, K. Ulm, U. Hoffmann, A. Assadian, M. Wildgruber, H.-H. Eckstein. (2011) WITHDRAWN: Rationale and Design of a Randomised Controlled Trial Comparing Stent-Protected Angioplasty with Bypass Surgery for Intermittent Claudication: The ABC Study. European Journal of Vascular and Endovascular Surgery
CrossRef166
José A.M. De Carvalho, Sílvia J. Piva, Bruna S. Hausen, Guilherme V. Bochi, Michelle Kaefer, Adriane C. Coelho, Marta M.M.F. Duarte, Rafael N. Moresco. (2011) Assessment of urinary γ-glutamyltransferase and alkaline phosphatase for diagnosis of diabetic nephropathy. Clinica Chimica Acta 412:15-16, 1407-1411
CrossRef167
Tomohiro Nishizawa, Karin E. Bornfeldt. (2011) Diabetic vascular disease and the potential role of macrophage glucose metabolism. Annals of Medicine1-9
CrossRef168
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Christina Hemmingsen, Jørn Wetterslev, Bianca Hemmingsen. 2011. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef169
Mitchell D. Weinberg, Joe F. Lau, Kenneth Rosenfield, Jeffrey W. Olin. (2011) Peripheral artery disease. Part 2: medical and endovascular treatment. Nature Reviews Cardiology 8:8, 429-441
CrossRef170
(2011) Intensive Glucose Lowering and Cardiovascular Outcomes. New England Journal of Medicine 364:23, 2263-2264
Full Text171
, L. G. Mellbin, K. Malmberg, A. Norhammar, H. Wedel, L. Rydén. (2011) Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54:6, 1308-1317
CrossRef172
Fang Chai, Yong Wang, Yong Zhou, Yuan Liu, Donghua Geng, Jingang Liu. (2011) Adiponectin Downregulates Hyperglycemia and Reduces Pancreatic Islet Apoptosis After Roux-En-Y Gastric Bypass Surgery. Obesity Surgery 21:6, 768-773
CrossRef173
David Benaiges Boix, Albert Goday Arno, Juan Pedro-Botet. (2011) La cirugía bariátrica como tratamiento de la diabetes tipo 2. Medicina Clínica
CrossRef174
Gina J. Ryan, Yolanda Hardy. (2011) Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics 36:3, 260-274
CrossRef175
Steven G. Chrysant, George S. Chrysant. (2011) Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. The American Journal of Cardiology 107:12, 1856-1861
CrossRef176
George Dailey. (2011) Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Clinical Therapeutics 33:6, 665-678
CrossRef177
M. A. Weir, T. Gomes, M. Mamdani, D. N. Juurlink, D. G. Hackam, J. L. Mahon, A. K. Jain, A. X. Garg. (2011) Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrology Dialysis Transplantation 26:6, 1888-1894
CrossRef178
Monika Lechleitner. (2011) Oral antidiabetic drug therapy in type 2 diabetes mellitus – focus on elderly patients. Wiener Medizinische Wochenschrift 161:11-12, 297-299
CrossRef179
Louis Monnier, Claude Colette, David Owens. (2011) Postprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts. Diabetes Technology & Therapeutics 13:S1, S-25-S-32
CrossRef180
Lawrence J. Schneiderman. (2011) Defining Medical Futility and Improving Medical Care. Journal of Bioethical Inquiry 8:2, 123-131
CrossRef181
Bernadette Mitchell, Carol Armour, Mary Lee, Yun Ju Song, Kay Stewart, Greg Peterson, Jeff Hughes, Lorraine Smith, Ines Krass. (2011) Diabetes Medication Assistance Service: The pharmacist's role in supporting patient self-management of type 2 diabetes (T2DM) in Australia. Patient Education and Counseling 83:3, 288-294
CrossRef182
Melissa Y. Tjota, Benjamin M. Kozak, Eric M. Chang, Kelly L. Close. (2011) Journal of Diabetes NEWS. Journal of Diabetes 3:2, 95-102
CrossRef183
Sophia Zoungas, Mark Woodward. (2011) Diabetes: Insights from the extended follow-up of the ACCORD trial. Nature Reviews Cardiology 8:6, 308-310
CrossRef184
S. Lim, M. K. Moon, H. Shin, T. H. Kim, B. J. Cho, M. Kim, H. S. Park, S. H. Choi, S.-H. Ko, M. H. Chung, I. K. Lee, H. C. Jang, Y.-B. Kim, K. S. Park. (2011) Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats. Cardiovascular Research 90:2, 383-393
CrossRef185
Katrien Benhalima, Eberhard Standl, Chantal Mathieu. (2011) The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. Journal of Diabetes and its Complications 25:3, 202-207
CrossRef186
A. Virkamäki, J. Saltevo. (2011) Finnish Current Care Guideline for Diabetes: interactive approach to improve individualised treatment. Diabetologia 54:5, 1264-1265
CrossRef187
W. Motz, W. Kerner. (2011) Kardiale Endorganschäden bei Diabetes. Der Internist 52:5, 505-517
CrossRef188
L. Czupryniak, E. Szymańska-Garbacz, M. Pawłowski, M. Saryusz-Wolska, J. Loba. (2011) In support of an early intensive treatment of type 2 diabetes and not necessarily of early polypharmacy. Diabetes, Obesity and Metabolism 13:5, 474-475
CrossRef189
Andreas Holstein, Michael Hahn, Olaf Patzer, Angela Seeringer, Peter Kovacs, Julia Stingl. (2011) Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. European Journal of Clinical Pharmacology 67:5, 471-476
CrossRef190
Adie Viljoen, Alan J. Sinclair. (2011) Diabetes and Insulin Resistance in Older People. Medical Clinics of North America 95:3, 615-629
CrossRef191
Karen N Eggleston, Nilay D Shah, Steven A Smith, Ernst R Berndt, Joseph P Newhouse. (2011) Quality Adjustment for Health Care Spending on Chronic Disease: Evidence from Diabetes Treatment, 1999–2009. American Economic Review 101:3, 206-211
CrossRef192
George L. Bakris. (2011) Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 86:5, 444-456
CrossRef193
-Wei Du Hong, -Yue Li Jia, He Yao. (2011) Glycemic and blood pressure control in older patients with hypertension and diabetes: association with carotid atherosclerosis. Journal of Geriatric Cardiology 8:1, 24-30
CrossRef194
Manuel Monreal. (2011) Factores de riesgo de complicaciones vasculares en extremidades inferiores en pacientes diabéticos. Medicina Clínica 136:9, 386-387
CrossRef195
Anthony L. McCall. (2011) What’s Wrong with Too Low? Is Hypoglycemia a Marker or a Cause of CVD and Mortality Risk?. Current Diabetes Reports 11:2, 71-74
CrossRef196
Bo Ahrén. (2011) Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. Current Diabetes Reports 11:2, 83-90
CrossRef197
Fernando Ovalle. (2011) Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes. Clinical Therapeutics 33:4, 393-407
CrossRef198
Sei J. Lee, W. John Boscardin, Irena Stijacic Cenzer, Elbert S. Huang, Kathy Rice-Trumble, Catherine Eng. (2011) The Risks and Benefits of Implementing Glycemic Control Guidelines in Frail Older Adults with Diabetes Mellitus. Journal of the American Geriatrics Society 59:4, 666-672
CrossRef199
Delphine S. Tuot, Neil R. Powe. (2011) Chronic Kidney Disease in Primary Care: An Opportunity for Generalists. Journal of General Internal Medicine 26:4, 356-358
CrossRef200
Matthew C Riddle. (2011) Glycemic control and cardiovascular mortality. Current Opinion in Endocrinology, Diabetes and Obesity 18:2, 104-109
CrossRef201
M. Schütt, H.H. Klein. (2011) Neue Möglichkeiten der Differenzialtherapie des Typ-2-Diabetes. Der Internist 52:4, 395-404
CrossRef202
A White, M Fisher. (2011) Making sense of outcomes in the ACCORD trial. Practical Diabetes International 28:3, 102-103
CrossRef203
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia. (2011) Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. Current Atherosclerosis Reports 13:2, 176-185
CrossRef204
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Atención Primaria 43:4, 202.e1-202.e9
CrossRef205
Amanda N. Long, Samuel Dagogo-Jack. (2011) Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. The Journal of Clinical Hypertension 13:4, 244-251
CrossRef206
Shin Kadota, Mitsuo Matsuda, Masayasu Izuhara, Osamu Baba, Hirokazu Mitsuoka, Keisuke Shioji, Takashi Uegaito. (2011) The association between post-load low insulin level and high mortality rates in patients with no previous diagnosis of diabetes mellitus. International Journal of Cardiology 148:1, 59-63
CrossRef207
Mariela Glandt, Zachary T. Bloomgarden. (2011) Hypertension in Diabetes: Treatment Considerations. The Journal of Clinical Hypertension 13:4, 314-318
CrossRef208
Daniel Addison, David Aguilar. (2011) Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies. Current Atherosclerosis Reports 13:2, 115-122
CrossRef209
P. Anagnostis, V. G. Athyros, F. Adamidou, A. Panagiotou, M. Kita, A. Karagiannis, D. P. Mikhailidis. (2011) Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes, Obesity and Metabolism 13:4, 302-312
CrossRef210
K. J. J. van Hateren, G. W. D. Landman, N. Kleefstra, I. Drion, K. H. Groenier, S. T. Houweling, H. J. G. Bilo. (2011) Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20). International Journal of Clinical Practice 65:4, 415-419
CrossRef211
Steven A. Smith. 2011. HbA1c: Is it the Most Important Therapeutic Target in outPatient Management of Diabetes?. , 96-104.
CrossRef212
Robert J. Richards, L. Yvonne Melendez-Ramirez, William T. Cefalu. 2011. Insulin Sensitizers Versus Secretagogues as First-Line Therapy for Diabetes: Rationale for Clinical Choice. , 71-78.
CrossRef213
Hana Rosolova, Barbora Nussbaumerova. (2011) Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. The EPMA Journal 2:1, 15-26
CrossRef214
J. H. DeVries. (2011) Intensified glucose lowering in type 2 diabetes: don’t throw the baby out with the bathwater. Diabetologia 54:3, 705-706
CrossRef215
J. S. Yudkin, B. Richter, E. A. M. Gale. (2011) Intensified glucose lowering in type 2 diabetes. Reply to Czupryniak L, Szymańska-Garbacz E, Pawłowski M et al. [letter], Aizawa T and Funase Y [letter] and DeVries JH [letter]. Diabetologia 54:3, 707-708
CrossRef216
J.-M. Halimi, Rédigé par D. Obreja. (2011) Protéger les reins des hypertendus. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011, S7-S9
CrossRef217
Yogish C Kudva, Ananda Basu. (2011) Ultra-long-acting insulins for a lifestyle-related pandemic. The Lancet 377:9769, 880-881
CrossRef218
Philip E Otterbeck, Mary Ann Banerji. (2011) The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications. Expert Review of Endocrinology & Metabolism 6:2, 143-151
CrossRef219
E. Menéndez Torre, J. Lafita Tejedor, S. Artola Menéndez, J. Millán Núñez-Cortés, Á. Alonso García, M. Puig Domingo, J.R. García Solans, F. Álvarez Guisasola, J. García Alegría, J. Mediavilla Bravo, C. Miranda Fernández-Santos, R. Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Revista Clínica Española 211:3, 147-155
CrossRef220
Sofiya Milman, Jill P. Crandall. (2011) Mechanisms of Vascular Complications in Prediabetes. Medical Clinics of North America 95:2, 309-325
CrossRef221
J.M. Galcerán. (2011) ¿Es posible prevenir la nefropatía diabética? El estudio ROADMAP. Hipertensión y Riesgo Vascular 28, 24-29
CrossRef222
Barbara J. Zarowitz. (2011) The ADA Focus on Diabetes 2011. Geriatric Nursing 32:2, 119-122
CrossRef223
Zafar H Israili. (2011) Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics 18:2, 117-152
CrossRef224
Kristina Sundquist, Åsa Chaikiat, Vania Ramírez León, Sven-Erik Johansson, Jan Sundquist. (2011) Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres. Diabetes/Metabolism Research and Reviews 27:3, 244-254
CrossRef225
DJ Galloway. (2011) Provision of laparoscopic bariatric surgery. Practical Diabetes International 28:2, 56-57
CrossRef226
Amit D Raval, Ketan Chovatiya, Ankit B Bhavsar, Megha H Patel, Amit D Raval. 2011. Dapagliflozin for type 2 diabetes mellitus. .
CrossRef227
2011. Type 2 Diabetes: General Introduction. , 83-101.
CrossRef228
Harold E. Lebovitz. (2011) Type 2 diabetes mellitus—current therapies and the emergence of surgical options. Nature Reviews Endocrinology 7:7, 408-419
CrossRef229
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Journal of the American College of Cardiology 57:8, 1002-1044
CrossRef230
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
CrossRef231
Mariel M Finucane, Gretchen A Stevens, Melanie J Cowan, Goodarz Danaei, John K Lin, Christopher J Paciorek, Gitanjali M Singh, Hialy R Gutierrez, Yuan Lu, Adil N Bahalim, Farshad Farzadfar, Leanne M Riley, Majid Ezzati. (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. The Lancet 377:9765, 557-567
CrossRef232
P. Chamnan, R. K. Simmons, R. Jackson, K. T. Khaw, N. J. Wareham, S. J. Griffin. (2011) Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. Diabetologia 54:2, 291-299
CrossRef233
Daniel M Tessier. (2011) Optimal glycemic control in the elderly: where is the evidence and who should be targeted?. Aging Health 7:1, 89-96
CrossRef234
Lal K. Tanwani. (2011) Insulin Therapy in the Elderly Patient With Diabetes. The American Journal of Geriatric Pharmacotherapy 9:1, 24-36
CrossRef235
P. Valensi, S. Picard. (2011) Lipids, lipid-lowering therapy and diabetes complications. Diabetes & Metabolism 37:1, 15-24
CrossRef236
Eisuke Yasunari, Kageumi Takeno, Hideaki Funayama, Setsuko Tomioka, Motoyuki Tamaki, Yoshio Fujitani, Ryuzo Kawamori, Hirotaka Watada, Takahisa Hirose. (2011) Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy. Journal of Diabetes Investigation 2:1, 56-62
CrossRef237
Hisako Hirai, Rie Kanaya, Morihiko Maeda, Ding qungfang, Koichiro Ina, Toshio Hayashi. (2011) The role of insulin growth factor on atherosclerosis and endothelial function: The effect on hyperlipidemia and aging. Life Sciences 88:9-10, 425-431
CrossRef238
Juliana CN Chan. (2011) What can we learn from the recent blood glucose lowering megatrials?. Journal of Diabetes Investigation 2:1, 1-5
CrossRef239
Sang Youl Rhee, Suk Chon, Mi Kwang Kwon, Ie Byung Park, Kyu Jeung Ahn, In Ju Kim, Sung-Hoon Kim, Hyoung Woo Lee, Kyung Soo Koh, Doo Man Kim, Sei Hyun Baik, Kwan Woo Lee, Moon Suk Nam, Yong Soo Park, Jeong-taek Woo, Young Seol Kim. (2011) Prevalence of Chronic Complications in Korean Patients with Type 2 Diabetes Mellitus Based on the Korean National Diabetes Program. Diabetes & Metabolism Journal 35:5, 504
CrossRef240
Ah Young Kang, Su Kyung Park, So Young Park, Hye Jeong Lee, Ying Han, Sa Ra Lee, Sung Hwan Suh, Duk Kyu Kim, Mi Kyoung Park. (2011) Therapeutic Target Achievement in Type 2 Diabetic Patients after Hyperglycemia, Hypertension, Dyslipidemia Management. Diabetes & Metabolism Journal 35:3, 264
CrossRef241
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Clínica e Investigación en Arteriosclerosis 23:1, 40-48
CrossRef242
M. Camafort, L. R. Álvarez-Rodríguez, J. F. S. Muñoz-Torrero, J. C. Sahuquillo, L. López-Jiménez, R. Coll, M. Monreal, . (2011) Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. Diabetic Medicine 28:1, 73-80
CrossRef243
Larry B. Goldstein, Ralph L. Sacco. 2011. Primary Prevention of Stroke. , 242-251.
CrossRef244
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor, Alice K. Jacobs, Sidney C. Smith, Jeffery L. Anderson, Cynthia D. Adams, Nancy Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Sharon Ann Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, Barbara Riegel, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef245
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. Endocrinología y Nutrición (English Edition) 58:3, 112-120
CrossRef246
Robert Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J Hoogwerf, Larry Shen. (2011) Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovascular Diabetology 10:1, 22
CrossRef247
Bruno Rodrigues, Kaleizu T Rosa, Alessandra Medeiros, Beatriz D Schaan, Patricia C Brum, Kátia De Angelis, Maria Irigoyen. (2011) Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovascular Diabetology 10:1, 26
CrossRef248
Shih-Hung Tsai, Yen-Yue Lin, Chin-Wang Hsu, Chien-Sheng Cheng, Der-Ming Chu. (2011) Hypoglycemia Revisited in the Acute Care Setting. Yonsei Medical Journal 52:6, 898
CrossRef249
Amit D Raval, Deval Gor, Arohi N Rangoonwala, Divyesh Thakker, Amit D Raval. 2011. .
CrossRef250
Lisa M Younk, Maia Mikeladze, Donna Tate, Stephen N Davis. (2011) Exercise-related hypoglycemia in diabetes mellitus. Expert Review of Endocrinology & Metabolism 6:1, 93-108
CrossRef251
Mark S. MacGregor, Maarten W. Taal. (2011) Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice 118:s1, c71-c100
CrossRef252
M.G. Hennerici. (2011) Report of the 20th European Stroke Conference, Hamburg, May 24–27, 2011. Cerebrovascular Diseases 32:6, 589-613
CrossRef253
Hyun Jeong Jeon, Tae Keun Oh. (2011) Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients. Diabetes & Metabolism Journal 35:5, 529
CrossRef254
Jung Hee Kim, Dae Jung Kim, Hak Chul Jang, Sung Hee Choi. (2011) Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea. Diabetes & Metabolism Journal 35:6, 571
CrossRef255
P. L. Drury, R. Ting, D. Zannino, C. Ehnholm, J. Flack, M. Whiting, R. Fassett, J.-C. Ansquer, P. Dixon, T. M. E. Davis, C. Pardy, P. Colman, A. Keech. (2011) Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 54:1, 32-43
CrossRef256
A D Wright, P M Dodson. (2011) Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye
CrossRef257
Ulrich M. Vischer. (2011) Glycemic Targets for Elderly Diabetic Patients Need Reappraisal. Journal of the American Medical Directors Association 12:1, 9-11
CrossRef258
Ebenezer A. Nyenwe, Terri W. Jerkins, Guillermo E. Umpierrez, Abbas E. Kitabchi. (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60:1, 1-23
CrossRef259
Wendy A Davis. (2011) Predicting severe hypoglycemia in the community: a review of recent evidence. Diabetes Management 1:1, 109-128
CrossRef260
Anadil Faqah, Tazeen H. Jafar. (2011) Control of Blood Pressure in Chronic Kidney Disease: How Low to Go. Nephron Clinical Practice 119:4, c324-c332
CrossRef261
Christoph Wanner, Vera Krane. (2011) Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research 34:4, 209-217
CrossRef262
Hiroshi Ito. (2011) Optimal treatment for coronary artery disease in patients with diabetes: percutaneous coronary intervention, coronary artery bypass graft, and medications. General Thoracic and Cardiovascular Surgery 59:1, 6-13
CrossRef263
Arthur J. Chu. (2011) Tissue Factor, Blood Coagulation, and Beyond: An Overview. International Journal of Inflammation 2011, 1-30
CrossRef264
Henry H Fischer, Sheri L Eisert, M Josh Durfee, Susan L Moore, Andrew W Steele, Kevin McCullen, Katherine Anderson, Lara Penny, Thomas D Mackenzie. (2011) The impact of tailored diabetes registry report cards on measures of disease control: a nested randomized trial. BMC Medical Informatics and Decision Making 11:1, 12
CrossRef265
Stephen J. Nicholls, E. Murat Tuzcu, Kathy Wolski, Ozgur Bayturan, Andrea Lavoie, Kiyoko Uno, Stuart Kupfer, Alfonso Perez, Richard Nesto, Steven E. Nissen. (2011) Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. Journal of the American College of Cardiology 57:2, 153-159
CrossRef266
Jerzy W. Kolaczynski. (2011) Concept paper: antihyperglycemic therapy and the diabetic heart—do we really know enough?. Journal of Diabetes and its Complications 25:1, 63-72
CrossRef267
Mário Raimundo, José António Lopes. (2011) Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad. Cardiology Research and Practice 2011, 1-16
CrossRef268
J. A. Johnson, S. L. Bowker. (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54:1, 25-31
CrossRef269
Keun-Hwa Jung, Kon Chu, Soon-Tae Lee, Jae-Jun Bahn, Jin-Hee Kim, Manho Kim, Sang Kun Lee, Jae-Kyu Roh. (2011) Risk of Macrovascular Complications in Type 2 Diabetes Mellitus: Endothelial Microparticle Profiles. Cerebrovascular Diseases 31:5, 485-493
CrossRef270
Hideo Fujita, Ryozo Nagai. (2011) Glycemic Control Is Another Target of PCI in Diabetic Patients. Circulation Journal 75:4, 773-774
CrossRef271
Donghong Fang, Hongyu Guan, Juan Liu, Guohong Wei, Weijian Ke, Bin Yao, Haipeng Xiao, Yanbing Li. (2011) Early intensive insulin therapy attenuates the p38 pathway in the renal cortex and indices of nephropathy in diabetic rats. Endocrine Journal
CrossRef272
Vladimir Vuksan, John Sievenpipper, Elena Jovanovski, Alexandra L. Jenkins. (2010) Current Clinical Evidence for Korean Red Ginseng in Management of Diabetes and Vascular Disease: A Toronto's Ginseng Clinical Testing Program. Journal of Ginseng Research 34:4, 264-273
CrossRef273
Alfonso Perez, Randal Jacks, Vipin Arora, Robert Spanheimer. (2010) Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared With Pioglitazone and Metformin Monotherapy in Patients With Type 2 Diabetes. The Journal of Clinical Hypertension 12:12, 973-982
CrossRef274
Philip Greenland, Joseph S. Alpert, George A. Beller, Emelia J. Benjamin, Matthew J. Budoff, Zahi A. Fayad, Elyse Foster, Mark A. Hlatky, John McB. Hodgson, Frederick G. Kushner, Michael S. Lauer, Leslee J. Shaw, Sidney C. Smith, Allen J. Taylor, William S. Weintraub, Nanette K. Wenger. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology 56:25, e50-e103
CrossRef275
David C. Klonoff. (2010) Incretin therapy for type 2 diabetes mellitus. Advances in Therapy 27:12, 881-894
CrossRef276
Luciano Pirola, Aneta Balcerczyk, Jun Okabe, Assam El-Osta. (2010) Epigenetic phenomena linked to diabetic complications. Nature Reviews Endocrinology 6:12, 665-675
CrossRef277
Laura Pala, Matteo Monami, Caterina Lamanna, Barbara Cresci, Claudia Colombi, Gianluca Bardini, Jolanda Sposato, Niccolò Marchionni, Carlo M. Rotella, Edoardo Mannucci. (2010) Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetologica 47:S1, 7-11
CrossRef278
S. Zervou, Y.-F. Wang, A. Laiho, A. Gyenesei, L. Kytömäki, R. Hermann, S. Abouna, D. Epstein, S. Pelengaris, M. Khan. (2010) Short-term hyperglycaemia causes non-reversible changes in arterial gene expression in a fully ‘switchable’ in vivo mouse model of diabetes. Diabetologia 53:12, 2676-2687
CrossRef279
Robert C. Atkins, Paul Zimmet. (2010) Diabetic kidney disease: Act now or pay later. Diabetes Research and Clinical Practice 90:3, e54-e56
CrossRef280
Taina K. Mattila, Anthonius de Boer. (2010) Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus. Drugs 70:17, 2229-2245
CrossRef281
M Brito-Sanfiel, J Diago-Cabezudo, A Calderon. (2010) Economic impact of hypoglycemia on healthcare in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, 649-660
CrossRef282
Bas Houweling, Martin Willink, Lex Goudswaard, Guy Rutten en Henk Bilo. (2010) Verwarring rond scherp instellen DM2. Huisarts en wetenschap
CrossRef283
J. Wernecke, A. Friedl. (2010) Therapieziele beim geriatrischen Patienten. Der Diabetologe 6:7, 551-559
CrossRef284
Toyoyoshi Uchida, Junko Kawai, Yoshio Fujitani, Ryuzo Kawamori, Hirotaka Watada, Takahisa Hirose. (2010) Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study. Diabetology International 1:1, 35-41
CrossRef285
G. David Batty, Qiang Li, Sébastien Czernichow, Bruce Neal, Sophia Zoungas, Rachel Huxley, Anushka Patel, Bastiaan E. de Galan, Mark Woodward, Pavel Hamet, Stephen B. Harrap, Neil Poulter, John Chalmers. (2010) Erectile Dysfunction and Later Cardiovascular Disease in Men With Type 2 Diabetes. Journal of the American College of Cardiology 56:23, 1908-1913
CrossRef286
Sophia Zoungas, Anushka Patel. (2010) Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Annals of the New York Academy of Sciences 1212:1, 29-40
CrossRef287
M. O. Gore, F. A. Masoudi, D. K. McGuire. (2010) Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a 'low ejection fraction' equivalent?. European Journal of Heart Failure 12:11, 1156-1158
CrossRef288
E. E. Wright, A. H. Stonehouse, R. M. Cuddihy. (2010) In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 12:11, 929-940
CrossRef289
R. Kahn. (2010) Guidelines: we’ll always need them, we sometimes dislike them, and we have to make them better. Diabetologia 53:11, 2280-2284
CrossRef290
K. Eeg-Olofsson, J. Cederholm, P. M. Nilsson, B. Zethelius, A.-M. Svensson, S. Gudbjörnsdóttir, B. Eliasson. (2010) New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Journal of Internal Medicine 268:5, 471-482
CrossRef291
A. Ceriello. (2010) The glucose triad and its role in comprehensive glycaemic control: current status, future management. International Journal of Clinical Practice 64:12, 1705-1711
CrossRef292
J. S. Skyler. (2010) Glycemia and cardiovascular diseases in type 2 diabetes. Journal of Internal Medicine 268:5, 468-470
CrossRef293
Mary Margaret Huizinga, Christianne L. Roumie, Robert A. Greevy, Xulei Liu, Harvey J. Murff, Adriana M. Hung, Carlos G. Grijalva, Marie R. Griffin. (2010) Glycemic and weight changes after persistent use of incident oral diabetes therapy: a veterans administration retrospective cohort study. Pharmacoepidemiology and Drug Safety 19:11, 1108-1112
CrossRef294
Patrick Murray, Gary W. Chune, Vasudevan A. Raghavan. (2010) Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials. Current Atherosclerosis Reports 12:6, 432-439
CrossRef295
, Q. Li, J. Chalmers, S. Czernichow, B. Neal, B. A. Taylor, S. Zoungas, N. Poulter, M. Woodward, A. Patel, B. Galan, G. D. Batty. (2010) Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Diabetologia 53:11, 2320-2327
CrossRef296
John Gerich. (2010) DPP-4 inhibitors: What may be the clinical differentiators?. Diabetes Research and Clinical Practice 90:2, 131-140
CrossRef297
T. Siegmund, P.M. Schumm-Draeger. (2010) Therapie mit oralen Antidiabetika und/oder Insulin im höheren Alter?. Der Diabetologe 6:7, 560-569
CrossRef298
David G. Sutin. (2010) DIABETES MELLITUS IN OLDER ADULTS: TIME FOR AN OVERTREATMENT QUALITY INDICATOR. Journal of the American Geriatrics Society 58:11, 2244-2245
CrossRef299
M. Buysschaert, V. Preumont, P.R. Oriot, I. Paris, M. Ponchon, D. Scarnière, P. Selvais. (2010) One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes & Metabolism 36:5, 381-388
CrossRef300
Giuseppe Tarantini, Davide Lanzellotti. (2010) Three-vessel coronary disease in diabetics: personalized versus evidence-based revascularization strategy. Future Cardiology 6:6, 797-809
CrossRef301
Francesco Boscia. (2010) Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema. Drugs 70:16, 2171-2200
CrossRef302
Zoungas, Sophia, Patel, Anushka, Chalmers, John, de Galan, Bastiaan E., Li, Qiang, Billot, Laurent, Woodward, Mark, Ninomiya, Toshiharu, Neal, Bruce, MacMahon, Stephen, Grobbee, Diederick E., Kengne, Andre Pascal, Marre, Michel, Heller, Simon, . (2010) Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine 363:15, 1410-1418
Full Text303
R. K. Simmons, J. B. Echouffo-Tcheugui, S. J. Griffin. (2010) Screening for type 2 diabetes: an update of the evidence. Diabetes, Obesity and Metabolism 12:10, 838-844
CrossRef304
V. Owen, I. Seetho, I. Idris. (2010) Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. Diabetes, Obesity and Metabolism 12:10, 865-870
CrossRef305
Lesley J. Scott. (2010) Alogliptin. Drugs 70:15, 2051-2072
CrossRef306
S. Halimi. (2010) Acute consequences of hypoglycaemia in diabetic patients. Diabetes & Metabolism 36, S75-S83
CrossRef307
J. S. Yudkin, B. Richter, E. A. M. Gale. (2010) Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:10, 2079-2085
CrossRef308
Yael Dinur Schejter, Elliot Turvall, Zvi Ackerman. (2010) Characteristics of Patients With Sulphonurea-Induced Hypoglycemia. Journal of the American Medical Directors Association
CrossRef309
Christian Coletti, Daniel J. Elliott, Marc T. Zubrow. (2010) Resident Perceptions of a Tele-Intensive Care Unit Implementation. Telemedicine and e-Health 16:8, 894-897
CrossRef310
Jothydev Kesavadev, Ashok Kumar Das, Ranjit Unnikrishnan, Shashank R. Joshi, Ambady Ramachandran, Jisha Shamsudeen, Gopika Krishnan, Sunitha Jothydev, Viswanathan Mohan. (2010) Use of Insulin Pumps in India: Suggested Guidelines Based on Experience and Cultural Differences. Diabetes Technology & Therapeutics 12:10, 823-831
CrossRef311
Stephan Jacob, Manuel Serrano-Gil. (2010) Engaging and empowering patients to manage their type 2 diabetes, Part II: Initiatives for success. Advances in Therapy 27:10, 665-680
CrossRef312
George Bakris, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers. (2010) National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International 78:8, 726-736
CrossRef313
I. Bourdel-Marchasson, A. Mouries, C. Helmer. (2010) Hyperglycaemia, microangiopathy, diabetes and dementia risk. Diabetes & Metabolism 36, S112-S118
CrossRef314
Lu-lu Chen, Yun-fei Liao, Tian-shu Zeng, Fan Yu, Hui-qing Li, Yong Feng. (2010) Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients. Endocrine 38:2, 266-275
CrossRef315
Jefferson Tilley, Joseph Grimsby, Shawn Erickson, Steven Berthel. 2010. Diabetes Drugs: Present and Emerging. .
CrossRef316
Jesse Foote, Jennifer Giuseffi, Medha N. Munshi. (2010) Diabetes in the Elderly. Current Cardiovascular Risk Reports 4:5, 347-353
CrossRef317
Sara Artola Menéndez. (2010) Panorama de los tratamientos actuales disponibles para los pacientes con diabetes tipo 2. Algoritmo terapéutico de la ADA/EASD. Seguridad y tolerabilidad. Atención Primaria 42, 24-32
CrossRef318
Hussein H. Karnib, Fuad N. Ziyadeh. (2010) The cardiorenal syndrome in diabetes mellitus. Diabetes Research and Clinical Practice 89:3, 201-208
CrossRef319
Francisco Javier Ampudia-Blasco, Antonio Ceriello. (2010) Importancia de la variabilidad del control glucémico diario en la consecución de los objetivos de control en la diabetes mellitus tipo 2: papel de los inhibidores de la dipeptidil peptidasa 4. Medicina Clínica 135, 33-39
CrossRef320
Javier Díez Espino. (2010) Diagnóstico y control de la diabetes mellitus tipo 2. Atención Primaria 42, 2-8
CrossRef321
José Miguel González Clemente, Gemma Llauradó Cabot. (2010) Parámetros de control glucémico: nuevas perspectivas en la evaluación del diabético. Medicina Clínica 135, 15-19
CrossRef322
P.P. Casado, J. Szymaniec, P. Conthe. (2010) ¿Qué ha cambiado en la estrategia terapéutica de la diabetes mellitus tipo 2?. Revista Clínica Española 210, 18-25
CrossRef323
Amulya T. Siram, Robert Yanagisawa, Maria Skamagas. (2010) Weight Management in Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, 533-548
CrossRef324
P.-J. Guillausseau. (2010) Should the algorithm for the treatment of type 2 diabetes be evidence-based?. Diabetologia 53:9, 2076-2077
CrossRef325
Pablo B. Pedrianes Martín, Pedro L. de Pablos Velasco. (2010) Seguridad y tolerabilidad de los antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2. Medicina Clínica 135, 20-26
CrossRef326
Urmimala Sarkar, Andrew J. Karter, Jennifer Y. Liu, Howard H. Moffet, Nancy E. Adler, Dean Schillinger. (2010) Hypoglycemia is More Common Among Type 2 Diabetes Patients with Limited Health Literacy: The Diabetes Study of Northern California (DISTANCE). Journal of General Internal Medicine 25:9, 962-968
CrossRef327
Hiroyuki Konya, Yoshikazu Hasegawa, Tomoya Hamaguchi, Kahori Satani, Akiko Umehara, Tomoyuki Katsuno, Tetsuya Ishikawa, Masayuki Miuchi, Kousuke Kohri, Akira Suehiro, Eizo Kakishita, Jun-ichiro Miyagawa, Mitsuyoshi Namba. (2010) Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism 59:9, 1294-1299
CrossRef328
Gissette Reyes-Soffer, Steve Holleran, Marco R. Di Tullio, Shunichi Homma, Bernadette Boden-Albala, Rajasekhar Ramakrishnan, Mitchell S. Elkind, Ralph L. Sacco, Henry N. Ginsberg. (2010) Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism 59:9, 1365-1371
CrossRef329
Jean-Pierre Grégoire, Caroline Sirois, Guillaume Blanc, Paul Poirier, Jocelyne Moisan. (2010) Persistence Patterns with Oral Antidiabetes Drug Treatment in Newly Treated Patients—A Population-Based Study. Value in Health 13:6, 820-828
CrossRef330
W.E. Feeman. (2010) Diabetes Mellitus Is Not a Coronary Heart Disease Equivalent. The American Journal of Cardiology 106:5, 754-755
CrossRef331
Dídac Mauricio, Ferran Rius. (2010) Controversias actuales en los objetivos de control glucémico. ¿Qué reflexiones exigen los resultados de los últimos estudios para abordar la diabetes mellitus tipo 2?. Medicina Clínica 135, 2-5
CrossRef332
Jean A. Ballweg. (2010) Hyperglycemia and neurodevelopmental outcomes in infants with congenital heart disease. Progress in Pediatric Cardiology 29:2, 107-111
CrossRef333
Billal Patel, Michael Fisher. (2010) Therapeutic advances in myocardial microvascular resistance: Unravelling the enigma. Pharmacology & Therapeutics 127:2, 131-147
CrossRef334
Faramarz Ismail-Beigi, Timothy Craven, Mary Ann Banerji, Jan Basile, Jorge Calles, Robert M Cohen, Robert Cuddihy, William C Cushman, Saul Genuth, Richard H Grimm, Bruce P Hamilton, Byron Hoogwerf, Diane Karl, Lois Katz, Armand Krikorian, Patrick O'Connor, Rodica Pop-Busui, Ulrich Schubart, Debra Simmons, Harris Taylor, Abraham Thomas, Daniel Weiss, Irene Hramiak. (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet 376:9739, 419-430
CrossRef335
E. S. Kilpatrick, A. S. Rigby, S. L. Atkin. (2010) For debate.Glucose variability and diabetes complication risk: we need to know the answer. Diabetic Medicine 27:8, 868-871
CrossRef336
Matthew A. Cavender, A. Michael Lincoff. (2010) Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist. American Journal Cardiovascular Drugs 10:4, 209-216
CrossRef337
D. Hill, M. Fisher. (2010) The effect of intensive glycaemic control on cardiovascular outcomes. Diabetes, Obesity and Metabolism 12:8, 641-647
CrossRef338
Margaret Bia, Deborah B. Adey, Roy D. Bloom, Laurence Chan, Sanjay Kulkarni, Steven Tomlanovich. (2010) KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Kidney Diseases 56:2, 189-218
CrossRef339
S. Zoungas, J. Chalmers, A.P. Kengne, A. Pillai, L. Billot, B. de Galan, M. Marre, B. Neal, S. Harrap, N. Poulter, A. Patel. (2010) The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Research and Clinical Practice 89:2, 126-133
CrossRef340
Ronald Klein. (2010) Intensive treatment of hyperglycaemia: ACCORD. The Lancet 376:9739, 391-392
CrossRef341
Anne Hiukka, Marianna Maranghi, Niina Matikainen, Marja-Riitta Taskinen. (2010) PPARα: an emerging therapeutic target in diabetic microvascular damage. Nature Reviews Endocrinology 6:8, 454-463
CrossRef342
M. L. Norgaard, S. S. Andersen, T. K. Schramm, F. Folke, C. H. Jørgensen, M. L. Hansen, C. Andersson, D. M. Bretler, A. Vaag, L. Køber, C. Torp-Pedersen, G. H. Gislason. (2010) Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study. Diabetologia 53:8, 1612-1619
CrossRef343
C. Nordin. (2010) The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 53:8, 1552-1561
CrossRef344
2010. Macrovascular Disease in Diabetes. , 152-160.
CrossRef345
2010. Hypoglycaemia. , 94-100.
CrossRef346
The ACCORD Study Group and ACCORD Eye Study Group. (2010) Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine 363:3, 233-244
Full Text347
Sally M. Marshall, Allan Flyvbjerg. 2010. Diabetic Nephropathy. , 599-614.
CrossRef348
Mohammed K. Ali, Mary Beth Weber, K. M. Venkat Narayan. 2010. The Global Burden of Diabetes. , 69-84.
CrossRef349
Richard I. G. Holt, Barry J. Goldstein. 2010. The Aims of Diabetes Care. , 323-333.
CrossRef350
Alan J. Sinclair. 2010. Diabetes in Old Age. , 922-939.
CrossRef351
Peter M. Nilsson, Adie Viljoen, Anthony S. Wierzbicki. 2010. Cardiovascular Risk Factors. , 657-683.
CrossRef352
Philip E. Cryer. 2010. Hypoglycemia in Diabetes. , 528-545.
CrossRef353
Riccardo Candido, Mark E. Cooper, Karin A. M. Jandeleit-Dahm. 2010. The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. , 635-656.
CrossRef354
Inga S. Thrainsdottir, Lars Rydén. 2010. Congestive Heart Failure. , 684-697.
CrossRef355
Ronald C. W. Ma, Peter C. Y. Tong. 2010. Epidemiology of Type 2 Diabetes. , 45-68.
CrossRef356
Dan Ziegler. 2010. Diabetic Peripheral Neuropathy. , 615-634.
CrossRef357
Joseph A. Aloi, Anthony L. McCall. 2010. How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. , 494-513.
CrossRef358
Clifford J. Bailey, Andrew J. Krentz. 2010. Oral Antidiabetic Agents. , 452-477.
CrossRef359
M. Stramba-Badiale. (2010) Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal 31:14, 1677-1681
CrossRef360
Ning Cheung, Paul Mitchell, Tien Yin Wong. (2010) Diabetic retinopathy. The Lancet 376:9735, 124-136
CrossRef361
G. Schernthaner, A. H. Barnett, D. J. Betteridge, R. Carmena, A. Ceriello, B. Charbonnel, M. Hanefeld, R. Lehmann, M. T. Malecki, R. Nesto, V. Pirags, A. Scheen, J. Seufert, A. Sjohölm, A. Tsatsoulis, R. DeFronzo. (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53:7, 1258-1269
CrossRef362
G. Schernthaner, E. Ritz, G.-H. Schernthaner. (2010) Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. Nephrology Dialysis Transplantation 25:7, 2044-2047
CrossRef363
A. H. Barnett, S. Cradock, M. Fisher, G. Hall, E. Hughes, A. Middleton. (2010) Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. International Journal of Clinical Practice 64:8, 1121-1129
CrossRef364
D. M. Mann, M. Woodward, P. Muntner. (2010) Preventing diabetes complications: are we too glucocentric?. International Journal of Clinical Practice 64:8, 1024-1027
CrossRef365
Jose M. Miguel-Yanes, James B. Meigs. (2010) Intensive-Therapy Glycemic Control Fails to Prevent Vascular Complications in Veterans with Type 2 Diabetes Mellitus. Current Cardiovascular Risk Reports 4:4, 248-250
CrossRef366
Pan Chang Yu, Zsolt Bosnyak, Antonio Ceriello. (2010) The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Research and Clinical Practice 89:1, 1-9
CrossRef367
H. Sourij, C. H. Saely, F. Schmid, R. Zweiker, T. Marte, T. C. Wascher, H. Drexel. (2010) Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. European Heart Journal 31:13, 1583-1590
CrossRef368
R. A. DeFronzo. (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:7, 1270-1287
CrossRef369
Julio Rosenstock, Vivian A. Fonseca, W. Timothy Garvey, Ronald B. Goldberg, Yehuda Handelsman, Stacey L. Abby, Yu-Ling Lai, Xiaoping Jin, Soamnauth Misir, Sukumar Nagendran, Michael R. Jones. (2010) Initial Combination Therapy With Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals in Early Type 2 Diabetes. Endocrine Practice 16:4, 629-640
CrossRef370
J.G. Garweg, A. Wenzel. (2010) Diabetische Makulopathie und Retinopathie. Der Ophthalmologe 107:7, 628-635
CrossRef371
J. Reckless, A. Robinson. (2010) Benefits and risks around glycaemic control in diabetes: where are we now?. International Journal of Clinical Practice 64:8, 1001-1003
CrossRef372
Jesús Millán Nú˜ez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2010) Riesgo vascular residual: recomendaciones de la Iniciativa Espa˜ola para la Reducción del Riesgo Residual. Medicina Clínica 135:4, 165-171
CrossRef373
Aparna Brown, L. Raymond Reynolds, Dennis Bruemmer. (2010) Intensive glycemic control and cardiovascular disease: an update. Nature Reviews Cardiology 7:7, 369-375
CrossRef374
Piero Ruggenenti, Paolo Cravedi, Giuseppe Remuzzi. (2010) The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology 6:6, 319-330
CrossRef375
Donald K. Zettervall, Laura Shane-McWhorter, Curtis Triplitt. (2010) Diabetes in the Elderly: Exercising Your Clinical Skills. The Consultant Pharmacist 25:0, 1-37
CrossRef376
Anthony H. Barnett. (2010) Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Current Medical Research and Opinion 26:6, 1333-1342
CrossRef377
Stephen Tonna, Assam El-Osta, Mark E. Cooper, Chris Tikellis. (2010) Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nature Reviews Nephrology 6:6, 332-341
CrossRef378
J. H. Martin, M. F. Fay. (2010) Surrogate end-points in clinical practice: are we providing worse care?. Internal Medicine Journal 40:6, 395-398
CrossRef379
I. Bourdel-Marchasson, E. Lapre, H. Laksir, E. Puget. (2010) Insulin resistance, diabetes and cognitive function: Consequences for preventative strategies. Diabetes & Metabolism 36:3, 173-181
CrossRef380
A. Schweizer, S. Dejager, J. E. Foley, A. Couturier, M. Ligueros-Saylan, W. Kothny. (2010) Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes, Obesity and Metabolism 12:6, 485-494
CrossRef381
G. Ko, W. So, P. Tong, R. Ma, A. Kong, R. Ozaki, C. Chow, C. Cockram, J. Chan. (2010) A simple risk score to identify Southern Chinese at high risk for diabetes. Diabetic Medicine 27:6, 644-649
CrossRef382
Massimo Volpe, Claudio Borghi, Paolo Cavallo Perin, Massimo Chiariello, Enzo Manzato, Roberto Miccoli, Maria Grazia Modena, Gabriele Riccardi, Giorgio Sesti, Antonio Tiengo, Bruno Trimarco, Diego Vanuzzo, Paolo Verdecchia, Augusto Zaninelli, Stefano Del Prato. (2010) Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure & Cardiovascular Prevention 17:2, 73-102
CrossRef383
D. R. Webb, K. Khunti, R. Silverman, L. J. Gray, B. Srinivasan, P. S. Lacy, B. Williams, M. J. Davies. (2010) Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia 53:6, 1190-1198
CrossRef384
Carl Erik Mogensen. (2010) Mistakes, misunderstandings and controversies in diabetes: A review and personal account. Journal of Diabetes Investigation 1:3, 97-100
CrossRef385
K. Khunti, M. Davies. (2010) Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes, Obesity and Metabolism 12:6, 474-484
CrossRef386
HELEN L PILMORE. (2010) Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology 15:4, 412-418
CrossRef387
Sherrie H. Kaplan, John Billimek, Dara H. Sorkin, Quyen Ngo-Metzger, Sheldon Greenfield. (2010) Who Can Respond to Treatment?. Medical Care 48, S9-S16
CrossRef388
Kathryn M. Hurren, Emily P. Bartley, Jessica L. O’Neill, David L. Ronis. (2010) Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes. Acta Diabetologica
CrossRef389
M. Gebregziabher, L. E. Egede, C. P. Lynch, C. Echols, Y. Zhao. (2010) Effect of Trajectories of Glycemic Control on Mortality in Type 2 Diabetes: A Semiparametric Joint Modeling Approach. American Journal of Epidemiology 171:10, 1090-1098
CrossRef390
R. De Caterina, R. Madonna. (2010) Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. European Heart Journal 31:10, 1159-1162
CrossRef391
Christian A. Schneider, Roman Pfister, Erland Erdmann. (2010) Diabetes und Herzinsuffizienz. Herz 35:3, 140-146
CrossRef392
A. I. Adler, S. Erqou, T. A. S. Lima, A. H. N. Robinson. (2010) Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis. Diabetologia 53:5, 840-849
CrossRef393
Vivian A. Fonseca, Yehuda Handelsman, Bart Staels. (2010) Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism 12:5, 384-392
CrossRef394
Bernd Stratmann, Thomas Gawlowski, Diethelm Tschoepe. (2010) Diabetic Cardiomyopathy – to Take a Long Story Serious. Herz 35:3, 161-168
CrossRef395
Ryu Miyagawa, Takefumi Asakura, Tomomi Nakamura, Hiromi Okada, Soichiro Iwaki, Burton E. Sobel, Satoshi Fujii. (2010) Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3′-untranslated region of the PAI-1 gene and its pharmacologic implications. Coronary Artery Disease 21:3, 144-150
CrossRef396
Ángeles Alonso-García, Francisco J. García-Soidán, Arturo Lisbona-Gil. (2010) Tratamiento hipoglucemiante en pacientes con diabetes mellitus tipo 2 con insuficiencia cardiaca estable o cardiopatía isquémica sin insuficiencia cardiaca. Medicina Clínica 134:13, 596-599
CrossRef397
Sabin Shurraw, Sumit R. Majumdar, Ravi Thadhani, Natasha Wiebe, Marcello Tonelli. (2010) Glycemic Control and the Risk of Death in 1,484 Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases 55:5, 875-884
CrossRef398
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef399
Yannis S. Guerra, Krishna Das, Pete Antonopoulos, Shane Borkowsky, Leon Fogelfeld, Melanie J. Gordon, Betsy M. Palal, Joanne C. Witsil, Evelyn A. Lacuesta. (2010) Computerized Physician Order Entry-Based Hyperglycemia Inpatient Protocol and Glycemic Outcomes: The CPOE-HIP Study. Endocrine Practice 16:3, 389-397
CrossRef400
I. W. Campbell. (2010) Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?. International Journal of Clinical Practice 64:6, 791-801
CrossRef401
Alice Y.Y. Cheng, Lawrence A. Leiter. (2010) Glucose lowering and cardiovascular disease: what do we know and what should we do?. European Journal of Cardiovascular Prevention & Rehabilitation 17, S25-S31
CrossRef402
Cristina Bianchi, Giuseppe Penno, Roberto Miccoli, Stefano Prato. (2010) Blood Glucose Control and Coronary Heart Disease. Herz 35:3, 148-159
CrossRef403
Paolo Pozzilli, R. David Leslie, Juliana Chan, Ralph De Fronzo, Louis Monnier, Itamar Raz, Stefano Del Prato. (2010) The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes/Metabolism Research and Reviews 26:4, 239-244
CrossRef404
, A. P. Kengne, A. Patel, S. Colagiuri, S. Heller, P. Hamet, M. Marre, C. Y. Pan, S. Zoungas, D. E. Grobbee, B. Neal, J. Chalmers, M. Woodward. (2010) The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 53:5, 821-831
CrossRef405
Nilsson, Peter M., . (2010) ACCORD and Risk-Factor Control in Type 2 Diabetes. New England Journal of Medicine 362:17, 1628-1630
Full Text406
W. Zhu, M. Chen, Q. Shou, Y. Li, F. Hu. (2010) Biological Activities of Chinese Propolis and Brazilian Propolis on Streptozotocin-Induced Type 1 Diabetes Mellitus in Rats. Evidence-based Complementary and Alternative Medicine
CrossRef407
L. Nalysnyk, M. Hernandez-Medina, G. Krishnarajah. (2010) Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes, Obesity and Metabolism 12:4, 288-298
CrossRef408
Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, Campbell D, Nicholls K, Tong A, Mangos G, Stack A, MacIsaac RJ, Girgis S, Colagiuri R, Colagiuri S, Craig J. (2010) Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology 15, S162-S194
CrossRef409
W. A. Davis, M. W. Knuiman, T. M. E. Davis. (2010) An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. Internal Medicine Journal 40:4, 286-292
CrossRef410
John Chalmers, Hisatomi Arima. (2010) Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE. Journal of Cardiovascular Pharmacology 55:4, 340-347
CrossRef411
Caroline S. Blaum, Christine T. Cigolle, Cynthia Boyd, Jennifer L. Wolff, Zhiyi Tian, Kenneth M. Langa, David R. Weir. (2010) Clinical Complexity in Middle-Aged and Older Adults With Diabetes. Medical Care 48:4, 327-334
CrossRef412
Kevin Niswender. (2010) Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes, Obesity and Metabolism 12:4, 267-287
CrossRef413
Edith M. Heintjes, Trine L. Thomsen, Fernie J. A. Penning-van Beest, Torsten E. Christensen, Ron M. C. Herings. (2010) Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Advances in Therapy 27:4, 211-222
CrossRef414
Oliver Schnell, Eberhard Standl. (2010) Diabetes and cardiovascular disease. Clinical Research in Cardiology Supplements 5:S1, 27-34
CrossRef415
E. Erdmann, R. Wilcox. (2010) Pioglitazone and mechanisms of CV protection. QJM 103:4, 213-228
CrossRef416
P. Valensi, E. Cosson. (2010) It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes & Metabolism 36:2, 91-96
CrossRef417
Caroline S. Fox. (2010) Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends in Cardiovascular Medicine 20:3, 90-95
CrossRef418
Juan J. Gagliardino, Line Kleinebreil, Stephen Colagiuri, Jeff Flack, Joaquín E. Caporale, Fernando Siri, Charles Clark. (2010) Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America. Diabetes Research and Clinical Practice 88:1, 7-13
CrossRef419
Maria M. Wanitschek, Otmar Pachinger, Hannes F. Alber. (2010) Ein „gefährliches Duo“. Wiener klinisches Magazin 13:2, 32-43
CrossRef420
Joshua M. Stolker, Dazhong Sun, Darcy G. Conaway, Philip G. Jones, Frederick A. Masoudi, Pamela N. Peterson, Harlan M. Krumholz, Mikhail Kosiborod, John A. Spertus. (2010) Importance of Measuring Glycosylated Hemoglobin in Patients With Myocardial Infarction and Known Diabetes Mellitus. The American Journal of Cardiology 105:8, 1090-1094
CrossRef421
Friedrich C. Luft. (2010) The time has come for incretins, a long time coming. Journal of Molecular Medicine 88:4, 319-321
CrossRef422
Richard Kahn, Peter Alperin, David Eddy, Knut Borch-Johnsen, John Buse, Justin Feigelman, Edward Gregg, Rury R Holman, M Sue Kirkman, Michael Stern, Jaakko Tuomilehto, Nick J Wareham. (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. The Lancet 375:9723, 1365-1374
CrossRef423
Richard M. Bergenstal, Clifford J. Bailey, David M. Kendall. (2010) Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications. The American Journal of Medicine 123:4, 374.e9-374.e18
CrossRef424
Natsuhiko Ehara, Takeshi Morimoto, Yutaka Furukawa, Satoshi Shizuta, Ryoji Taniguchi, Yoshihisa Nakagawa, Kozo Hoshino, Naritatsu Saito, Takahiro Doi, Yoshisumi Haruna, Neiko Ozasa, Yukiko Imai, Satoshi Teramukai, Masanori Fukushima, Toru Kita, Takeshi Kimura. (2010) Effect of Baseline Glycemic Level on Long-Term Cardiovascular Outcomes After Coronary Revascularization Therapy in Patients With Type 2 Diabetes Mellitus Treated With Hypoglycemic Agents. The American Journal of Cardiology 105:7, 960-966
CrossRef425
Benjamin R. McClintic, Jedediah I. McClintic, John D. Bisognano, Robert C. Block. (2010) The Relationship between Retinal Microvascular Abnormalities and Coronary Heart Disease: A Review. The American Journal of Medicine 123:4, 374.e1-374.e7
CrossRef426
Selvin, Elizabeth, Steffes, Michael W., Zhu, Hong, Matsushita, Kunihiro, Wagenknecht, Lynne, Pankow, James, Coresh, Josef, Brancati, Frederick L., . (2010) Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. New England Journal of Medicine 362:9, 800-811
Full Text427
Matteo Anselmino, Klas Malmberg, Linda Mellbin, Lars Rydén. (2010) Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. Reviews in Endocrine and Metabolic Disorders 11:1, 87-94
CrossRef428
Jean-Paul Chapelle, Jelda Teixeira, Diane Maisin, Hans Assink, Gerhard Barla, An K. Stroobants, Barend Delzenne, Wouter van den Eshof. (2010) Multicentre evaluation of the Tosoh HbA1c G8 analyser. Clinical Chemistry and Laboratory Medicine 48:3, 365-371
CrossRef429
Naushira Pandya, Esther Nathanson. (2010) Managing Diabetes in Long-Term Care Facilities: Benefits of Switching From Human Insulin to Insulin Analogs. Journal of the American Medical Directors Association 11:3, 171-178
CrossRef430
Robert C. Atkins, Paul Zimmet. (2010) Diabetic kidney disease: Act now or pay later. Acta Physiologica Hungarica 97:1, 52-56
CrossRef431
Jamshid Shirani, Vasken Dilsizian. (2010) Screening Asymptomatic Patients with Type 2 Diabetes Mellitus for Coronary Artery Disease: Does It Improve Patient Outcome?. Current Cardiology Reports 12:2, 140-146
CrossRef432
Robert G. Nelson, Katherine R. Tuttle. (2010) Prevention of Diabetic Kidney Disease: Negative Clinical Trials With Renin-Angiotensin System Inhibitors. American Journal of Kidney Diseases 55:3, 426-430
CrossRef433
H. K. Berthold, K. P. Bestehorn, W. Krone, I. Gouni-Berthold. (2010) Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. Diabetic Medicine 27:3, 303-308
CrossRef434
Gerald W. Smetana, Jane S. Sillman. (2010) Update in New Medications for Primary Care. Journal of General Internal Medicine 25:3, 261-269
CrossRef435
Csaba P. Kovesdy, Jong C. Park, Kamyar Kalantar-Zadeh. (2010) Glycemic Control and Burnt-Out Diabetes in ESRD. Seminars in Dialysis 23:2, 148-156
CrossRef436
Cristina M. Sena, Carla F. Bento, Paulo Pereira, Raquel Seiça. (2010) Diabetes mellitus: new challenges and innovative therapies. The EPMA Journal 1:1, 138-163
CrossRef437
Radica Z. Alicic, Katherine R. Tuttle. (2010) Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis 23:2, 140-147
CrossRef438
L. Venskutonyte, K. Malmberg, A. Norhammar, H. Wedel, L. Rydén. (2010) Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. Journal of Internal Medicine
CrossRef439
Shailesh Nandish, Jamison Wyatt, Rene Oliveros, Adrienne Stevens Zion, Michael Lujan, Robert Chilton. (2010) A Cardiologist’s View of Hypoglycemia. Current Atherosclerosis Reports 12:2, 88-95
CrossRef440
PS Sharp. (2010) Glycaemic outcomes following discharge from an intermediate care diabetes clinic. Practical Diabetes International 27:2, 53-54
CrossRef441
John P. D. Reckless. (2010) How much will Incretin Mimetics contribute to hyperglycaemia management?. International Journal of Clinical Practice 64:4, 418-420
CrossRef442
Ken Fujioka. (2010) Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:3, 186-194
CrossRef443
Robert C. Atkins, Paul Zimmet. (2010) Diabetic kidney disease: act now or pay later. Acta Diabetologica 47:1, 1-4
CrossRef444
M. L. Simoons, S. Windecker. (2010) Chronic stable coronary artery disease: drugs vs. revascularization. European Heart Journal 31:5, 530-541
CrossRef445
Eli A. Friedman. (2010) Continuously Evolving Management Concepts for Diabetic CKD and ESRD. Seminars in Dialysis 23:2, 134-139
CrossRef446
Corey E. Tabit, William B. Chung, Naomi M. Hamburg, Joseph A. Vita. (2010) Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders 11:1, 61-74
CrossRef447
Sohita Dhillon. (2010) Sitagliptin. Drugs 70:4, 489-512
CrossRef448
Harish Iyer, Anand Khedkar, Manish Verma. (2010) Oral insulin - a review of current status. Diabetes, Obesity and Metabolism 12:3, 179-185
CrossRef449
Robert C Atkins, Paul Zimmet. (2010) Diabetic kidney disease: act now or pay later. Kidney International 77:5, 375-377
CrossRef450
Hylton V. Joffe, Mary H. Parks, Robert Temple. (2010) Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 11:1, 21-30
CrossRef451
Kirsten Howard, Sarah White, Glenn Salkeld, Stephen McDonald, Jonathan C. Craig, Steven Chadban, Alan Cass. (2010) Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis. Value in Health 13:2, 196-208
CrossRef452
I. Oluwatowoju, E. Abu, S. H. Wild, C. D. Byrne. (2010) Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of diabetes care in the UK. Diabetic Medicine 27:3, 354-359
CrossRef453
Diana Hortensia Barbonta, Christopher William Loughlan, JE Claire Dickerson, Diana Hortensia Barbonta. 2010. Pramlintide for diabetes mellitus. .
CrossRef454
(2010) Diabetic kidney disease: Act now or pay later. Nephrology 15:1, 20-22
CrossRef455
Beverley Balkau, Dominique Simon. (2010) Survival in people with type 2 diabetes as a function of HbA1c. The Lancet 375:9713, 438-440
CrossRef456
R. Roussel, E. Cosson. (2010) Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!. Diabetes & Metabolism 36:1, 86-87
CrossRef457
Robert C. Atkins, Paul Zimmet. (2010) Diabetic kidney disease: act now or pay later. Pediatric Nephrology 25:2, 181-184
CrossRef458
R. C. Atkins, P. Zimmet. (2010) Diabetic kidney disease: act now or pay later. Nephrology Dialysis Transplantation 25:2, 331-333
CrossRef459
Hubert Kolb, Kerstin Kempf, Stephan Martin, Michael Stumvoll, Rüdiger Landgraf. (2010) On what evidence-base do we recommend self-monitoring of blood glucose?. Diabetes Research and Clinical Practice 87:2, 150-156
CrossRef460
Abd A. Tahrani, Milan K. Piya, Amy Kennedy, Anthony H. Barnett. (2010) Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacology & Therapeutics 125:2, 328-361
CrossRef461
Robert C. Atkins, Paul Zimmet. (2010) World Kidney Day 2010: Diabetic Kidney Disease—Act Now or Pay Later. American Journal of Kidney Diseases 55:2, 205-208
CrossRef462
S. Garg, I. B. Hirsch. (2010) Self-monitoring of blood glucose. International Journal of Clinical Practice 64, 1-10
CrossRef463
Josée Dupuis, Claudia Langenberg, Inga Prokopenko, Richa Saxena, Nicole Soranzo, Anne U Jackson, Eleanor Wheeler, Nicole L Glazer, Nabila Bouatia-Naji, Anna L Gloyn, Cecilia M Lindgren, Reedik Mägi, Andrew P Morris, Joshua Randall, Toby Johnson, Paul Elliott, Denis Rybin, Gudmar Thorleifsson, Valgerdur Steinthorsdottir, Peter Henneman, Harald Grallert, Abbas Dehghan, Jouke Jan Hottenga, Christopher S Franklin, Pau Navarro, Kijoung Song, Anuj Goel, John R B Perry, Josephine M Egan, Taina Lajunen, Niels Grarup, Thomas Sparsø, Alex Doney, Benjamin F Voight, Heather M Stringham, Man Li, Stavroula Kanoni, Peter Shrader, Christine Cavalcanti-Proença, Meena Kumari, Lu Qi, Nicholas J Timpson, Christian Gieger, Carina Zabena, Ghislain Rocheleau, Erik Ingelsson, Ping An, Jeffrey O'Connell, Jian'an Luan, Amanda Elliott, Steven A McCarroll, Felicity Payne, Rosa Maria Roccasecca, François Pattou, Praveen Sethupathy, Kristin Ardlie, Yavuz Ariyurek, Beverley Balkau, Philip Barter, John P Beilby, Yoav Ben-Shlomo, Rafn Benediktsson, Amanda J Bennett, Sven Bergmann, Murielle Bochud, Eric Boerwinkle, Amélie Bonnefond, Lori L Bonnycastle, Knut Borch-Johnsen, Yvonne Böttcher, Eric Brunner, Suzannah J Bumpstead, Guillaume Charpentier, Yii-Der Ida Chen, Peter Chines, Robert Clarke, Lachlan J M Coin, Matthew N Cooper, Marilyn Cornelis, Gabe Crawford, Laura Crisponi, Ian N M Day, Eco J C de Geus, Jerome Delplanque, Christian Dina, Michael R Erdos, Annette C Fedson, Antje Fischer-Rosinsky, Nita G Forouhi, Caroline S Fox, Rune Frants, Maria Grazia Franzosi, Pilar Galan, Mark O Goodarzi, Jürgen Graessler, Christopher J Groves, Scott Grundy, Rhian Gwilliam, Ulf Gyllensten, Samy Hadjadj, Göran Hallmans, Naomi Hammond, Xijing Han, Anna-Liisa Hartikainen, Neelam Hassanali, Caroline Hayward, Simon C Heath, Serge Hercberg, Christian Herder, Andrew A Hicks, David R Hillman, Aroon D Hingorani, Albert Hofman, Jennie Hui, Joe Hung, Bo Isomaa, Paul R V Johnson, Torben Jørgensen, Antti Jula, Marika Kaakinen, Jaakko Kaprio, Y Antero Kesaniemi, Mika Kivimaki, Beatrice Knight, Seppo Koskinen, Peter Kovacs, Kirsten Ohm Kyvik, G Mark Lathrop, Debbie A Lawlor, Olivier Le Bacquer, Cécile Lecoeur, Yun Li, Valeriya Lyssenko, Robert Mahley, Massimo Mangino, Alisa K Manning, María Teresa Martínez-Larrad, Jarred B McAteer, Laura J McCulloch, Ruth McPherson, Christa Meisinger, David Melzer, David Meyre, Braxton D Mitchell, Mario A Morken, Sutapa Mukherjee, Silvia Naitza, Narisu Narisu, Matthew J Neville, Ben A Oostra, Marco Orrù, Ruth Pakyz, Colin N A Palmer, Giuseppe Paolisso, Cristian Pattaro, Daniel Pearson, John F Peden, Nancy L Pedersen, Markus Perola, Andreas F H Pfeiffer, Irene Pichler, Ozren Polasek, Danielle Posthuma, Simon C Potter, Anneli Pouta, Michael A Province, Bruce M Psaty, Wolfgang Rathmann, Nigel W Rayner, Kenneth Rice, Samuli Ripatti, Fernando Rivadeneira, Michael Roden, Olov Rolandsson, Annelli Sandbaek, Manjinder Sandhu, Serena Sanna, Avan Aihie Sayer, Paul Scheet, Laura J Scott, Udo Seedorf, Stephen J Sharp, Beverley Shields, Gunnar Sigurðsson, Eric J G Sijbrands, Angela Silveira, Laila Simpson, Andrew Singleton, Nicholas L Smith, Ulla Sovio, Amy Swift, Holly Syddall, Ann-Christine Syvänen, Toshiko Tanaka, Barbara Thorand, Jean Tichet, Anke Tönjes, Tiinamaija Tuomi, André G Uitterlinden, Ko Willems van Dijk, Mandy van Hoek, Dhiraj Varma, Sophie Visvikis-Siest, Veronique Vitart, Nicole Vogelzangs, Gérard Waeber, Peter J Wagner, Andrew Walley, G Bragi Walters, Kim L Ward, Hugh Watkins, Michael N Weedon, Sarah H Wild, Gonneke Willemsen, Jaqueline C M Witteman, John W G Yarnell, Eleftheria Zeggini, Diana Zelenika, Björn Zethelius, Guangju Zhai, Jing Hua Zhao, M Carola Zillikens, Ingrid B Borecki, Ruth J F Loos, Pierre Meneton, Patrik K E Magnusson, David M Nathan, Gordon H Williams, Andrew T Hattersley, Kaisa Silander, Veikko Salomaa, George Davey Smith, Stefan R Bornstein, Peter Schwarz, Joachim Spranger, Fredrik Karpe, Alan R Shuldiner, Cyrus Cooper, George V Dedoussis, Manuel Serrano-Ríos, Andrew D Morris, Lars Lind, Lyle J Palmer, Frank B Hu, Paul W Franks, Shah Ebrahim, Michael Marmot, W H Linda Kao, James S Pankow, Michael J Sampson, Johanna Kuusisto, Markku Laakso, Torben Hansen, Oluf Pedersen, Peter Paul Pramstaller, H Erich Wichmann, Thomas Illig, Igor Rudan, Alan F Wright, Michael Stumvoll, Harry Campbell, James F Wilson, Richard N Bergman, Thomas A Buchanan, Francis S Collins, Karen L Mohlke, Jaakko Tuomilehto, Timo T Valle, David Altshuler, Jerome I Rotter, David S Siscovick, Brenda W J H Penninx, Dorret I Boomsma, Panos Deloukas, Timothy D Spector, Timothy M Frayling, Luigi Ferrucci, Augustine Kong, Unnur Thorsteinsdottir, Kari Stefansson, Cornelia M van Duijn, Yurii S Aulchenko, Antonio Cao, Angelo Scuteri, David Schlessinger, Manuela Uda, Aimo Ruokonen, Marjo-Riitta Jarvelin, Dawn M Waterworth, Peter Vollenweider, Leena Peltonen, Vincent Mooser, Goncalo R Abecasis, Nicholas J Wareham, Robert Sladek, Philippe Froguel, Richard M Watanabe, James B Meigs, Leif Groop, Michael Boehnke, Mark I McCarthy, Jose C Florez, Inês Barroso. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics 42:2, 105-116
CrossRef464
M. Hanefeld, C. Koehler, C. Hoffmann, K. Wilhelm, W. Kamke, H. Gerstein. (2010) Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabetic Medicine 27:2, 175-180
CrossRef465
J. K. Cruickshank. (2010) Low-dose thiazide diuretics in and around diabetes-definitely yes, and how do they compare with other interventions?. Diabetic Medicine 27:2, 127-129
CrossRef466
Robert C Atkins, Paul Zimmet. (2010) Diabetic kidney disease: Act now or pay later. Journal of Hypertension 28:2, 408-410
CrossRef467
Edward S. Horton. (2010) Challenges and Approaches to Managing Type 2 Diabetes Mellitus. Current Diabetes Reports 10:1, 7-9
CrossRef468
(2010) Diabetic Kidney Disease: Act Now or Pay Later-World Kidney Day, 11 March 2010. Therapeutic Apheresis and Dialysis 14:1, 1-4
CrossRef469
Craig J Currie, John R Peters, Aodán Tynan, Marc Evans, Robert J Heine, Oswaldo L Bracco, Tony Zagar, Chris D Poole. (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. The Lancet 375:9713, 481-489
CrossRef470
Swapnil N. Rajpathak, Vikas Aggarwal, Frank B. Hu. (2010) Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes. Current Diabetes Reports 10:1, 16-23
CrossRef471
A. Fritsche, M. Larbig, D. Owens, H.-U. Häring, . (2010) Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes, Obesity and Metabolism 12:2, 115-123
CrossRef472
Sung Hyuk Heo, Seung-Hoon Lee, Beom Joon Kim, Bong Su Kang, Byung Woo Yoon. (2010) Does glycated hemoglobin have clinical significance in ischemic stroke patients?. Clinical Neurology and Neurosurgery 112:2, 98-102
CrossRef473
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef474
Siobhan HM Brown, Ahmed H Abdelhafiz. (2010) Hypoglycemia, intensive glycemic control and diabetes care in care home residents with Type 2 diabetes. Aging Health 6:1, 31-40
CrossRef475
Sandra L. Tunis, William D. Willis, Volker Foos. (2010) Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. Current Medical Research and Opinion 26:1, 163-175
CrossRef476
Kouichiro Aihara, Katsumi Miyauchi, Takatoshi Kasai, Naozumi Kubota, Kan Kajimoto, Hiroshi Tamura, Takahiko Kojima, Ken Yokoyama, Takeshi Kurata, Atsushi Amano, Hiroyuki Daida. (2010) Long-Term Efficacy of Pravastatin Therapy in Diabetic Patients Undergoing Complete Coronary Revascularization. Journal of Atherosclerosis and Thrombosis 17:4, 350-355
CrossRef477
Torgeir Søvik, Babak Irandoust, Kåre Birkeland, Erlend Aasheim, Carl Schou, Jon Kristinsson, Tom Mala. (2010) Type 2-diabetes og metabolsk syndrom før og etter gastrisk bypass. Tidsskrift for Den norske legeforening 130:13, 1347-1350
CrossRef478
Kenzo Oba, Hiroshi Nakano, Yoshimasa Igari. (2010) Clinical guidelines for elderly patients with diabetes mellitus. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:6, 517-521
CrossRef479
J. S. Yudkin, B. Richter. (2010) Using individual patient data in meta-analyses of glucose-lowering studies. Diabetologia 53:1, 216-217
CrossRef480
Tomonari Okada, Tamami Yamanaka, Ryo Tomaru, Tokiyo Tamekuni, Shinga Esaki, Tomoka Nango, Yoshitaka Miyaoka, Toshiyuki Nakao, Katsusuke Ikeda. (2010) Relationship among glycated albumin, hemoglobin A1c, and daily blood glucose profile in diabetic patients on chronic hemodialysis. Nihon Toseki Igakkai Zasshi 43:5, 433-441
CrossRef481
Gregory A. Nichols, Shravanthi R. Gandra, Chiun-Fang Chiou, Mary S. Anthony, Maria Alexander-Bridges, Jonathan B. Brown. (2010) Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. Current Medical Research and Opinion 26:1, 9-15
CrossRef482
Kenro Nishida, Seiya Shimoda, Kenshi Ichinose. (2010) Glucose control in critically ill patients and clinical application of bedside-type artificial endocrine pancreas. Nihon Shuchu Chiryo Igakukai zasshi 17:4, 464-467
CrossRef483
Alberto Cordero, Lorenzo Fácila, Enrique Galve, Pilar Mazón. (2010) Novedades en hipertensión arterial y diabetes mellitus. Revista Española de Cardiología 63, 101-115
CrossRef484
Taiji Yamashita, Morihiro Matsuda, Orie Nishimoto, Kei Nakamoto, Hirohiko Nishiyama, Kengo Matsumoto, Ritsu Tamura, Toshiharu Kawamoto. (2010) Combination of Serum Adiponectin Level and Metabolic Syndrome is Closely Associated with Coronary Artery Disease in Japanese Subjects with Good Glycemic Control. Internal Medicine 49:8, 721-727
CrossRef485
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef486
Masafumi NAKAYAMA. (2010) S14-4. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:3, 99S-100s
CrossRef487
Shinichiro UEDA. (2010) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:3, 90-94
CrossRef488
N. V. Emanuele. (2010) Duration of diabetes, glucose control and cardiovascular risk. Diabetologia 53:1, 214-215
CrossRef489
B. Gallwitz, H.-U. Häring. (2010) Future perspectives for insulinotropic agents in the treatment of type 2 diabetesâDPP-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 12:1, 1-11
CrossRef490
M. Halbron. (2010) Gestione terapeutica del diabete di tipo 2. EMC - AKOS - Trattato di Medicina 12:4, 1-7
CrossRef491
J Boyle, M Fisher. (2010) The addition of insulin to metformin and sulphonylureas: results of the 4-T study. Practical Diabetes International 27:1, 5-6
CrossRef492
(2010) Añadir insulina de acción lenta. Dr. J.A. Martin Oterino. Revista Clínica Española 210:1, 26-27
CrossRef493
Barry Greenberg. (2010) Pre-Clinical Diastolic Dysfunction in Diabetic Patients. Journal of the American College of Cardiology 55:4, 306-308
CrossRef494
G. Paolisso, A. J. Sinclair. (2010) Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. The journal of nutrition, health & aging 14:1, 3-4
CrossRef495
J.-M. Gamble, S. H. Simpson, D. T. Eurich, S. R. Majumdar, J. A. Johnson. (2010) Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes, Obesity and Metabolism 12:1, 47-53
CrossRef496
Paola Fioretto, Paul M. Dodson, Dan Ziegler, Robert S. Rosenson. (2010) Residual microvascular risk in diabetes: unmet needs and future directions. Nature Reviews Endocrinology 6:1, 19-25
CrossRef497
A D Wright, P M Dodson. (2010) Diabetic retinopathy and blockade of the renin–angiotensin system: new data from the DIRECT study programme. Eye 24:1, 1-6
CrossRef498
Sunao Kojima, Tomohiro Sakamoto, Hisao Ogawa, Akira Kitagawa, Kunihiko Matsui, Hideki Shimomura, Kazuo Kimura, Yasuhiro Ogata, Naritsugu Sakaino, The Multicenter Study for Aggressiv. (2010) Standard-Dose Statin Therapy Provides Incremental Clinical Benefits in Normocholesterolemic Diabetic Patients. Circulation Journal 74:4, 779-785
CrossRef499
Tamara B. Horwich, Gregg C. Fonarow. (2010) Glucose, Obesity, Metabolic Syndrome, and Diabetes. Journal of the American College of Cardiology 55:4, 283-293
CrossRef500
Shari S. Bassuk, JoAnn E. Manson. 2010. Gender-Specific Aspects of Selected Coronary Heart Disease Risk FactorsA Summary of the Epidemiologic Evidence. , 162-174.
CrossRef501
Adam Whaley-Connell, L. Romayne Kurukulasuriya, James R. Sowers. (2009) Renin-Angiotensin-Aldosterone System Inhibition and Improvement in Glucose Tolerance. The Journal of Clinical Hypertension 11, S40-S47
CrossRef502
Dieter Mesotten, Greet Van den Berghe. (2009) Clinical benefits of tight glycaemic control: focus on the intensive care unit. Best Practice & Research Clinical Anaesthesiology 23:4, 421-429
CrossRef503
J.-M. Halimi, R. Asmar, J. Ribstein. (2009) Optimal nephroprotection: Use, misuse and misconceptions about blockade of the renin–angiotensin system. Lessons from the ONTARGET and other recent trials. Diabetes & Metabolism 35:6, 425-430
CrossRef504
Mahamood Edavalath, Alan Rees. (2009) Therapy and clinical trials: glycaemic control and cardiovascular disease. Current Opinion in Lipidology 20:6, 530-531
CrossRef505
Yoshikane Izawa, Shinichi Takahashi, Norihiro Suzuki. (2009) Pioglitazone enhances pyruvate and lactate oxidation in cultured neurons but not in cultured astroglia. Brain Research 1305, 64-73
CrossRef506
B. Guthrie, A. Emslie-Smith, A. D. Morris. (2009) Which people with Type 2 diabetes achieve good control of intermediate outcomes? Population database study in a UK region. Diabetic Medicine 26:12, 1269-1276
CrossRef507
M. J. Davies, R. Donnelly, A. H. Barnett, S. Jones, C. Nicolay, A. Kilcoyne. (2009) Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism 11:12, 1153-1162
CrossRef508
Stephan F. E. Praet, Luc J. C. Loon. (2009) Exercise therapy in Type 2 diabetes. Acta Diabetologica 46:4, 263-278
CrossRef509
F. Oriente, S. Iovino, A. Cassese, C. Romano, C. Miele, G. Troncone, M. Balletta, A. Perfetti, G. Santulli, G. Iaccarino, R. Valentino, F. Beguinot, P. Formisano. (2009) Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-β activity and TGF-β1 expression. Diabetologia 52:12, 2642-2652
CrossRef510
Angela Marie Abbatecola, Giuseppe Paolisso, Andrea Corsonello, Silvia Bustacchini, Fabrizia Lattanzio. (2009) Antidiabetic Oral Treatment in Older People. Drugs & Aging 26:Supplement 1, 53-62
CrossRef511
Ivan Tkáč, Zvonko Milićević, György Jermendy. (2009) How to interpret results of the HEART2D trial?. Diabetes Research and Clinical Practice 86, S53-S56
CrossRef512
Toshiko Uchida, Stephen D. Persell, David W. Baker. (2009) Update in General Internal Medicine. Journal of General Internal Medicine 24:12, 1327-1332
CrossRef513
D. John Betteridge. (2009) CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundamental & Clinical Pharmacology 23:6, 675-679
CrossRef514
Jan Gunst, Miet Schetz. (2009) Clinical benefits of tight glycaemic control: effect on the kidney. Best Practice & Research Clinical Anaesthesiology 23:4, 431-439
CrossRef515
F. Follath. (2009) Ethical considerations in cardiovascular prevention. Fundamental & Clinical Pharmacology 23:6, 669-673
CrossRef516
Zachary Bloomgarden. (2009) Recent cardiovascular trials: What are the drivers of benefit and adverse effect?. Journal of Diabetes 1:4, 227-229
CrossRef517
Ivan Tkáč. (2009) Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. Diabetes Research and Clinical Practice 86, S57-S62
CrossRef518
Mary Ann Vann. (2009) Perioperative management of ambulatory surgical patients with diabetes mellitus. Current Opinion in Anaesthesiology 22:6, 718-724
CrossRef519
Mark E. Williams. (2009) Management of diabetes in dialysis patients. Current Diabetes Reports 9:6, 466-472
CrossRef520
Leszek Czupryniak. (2009) Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations?. Diabetes Research and Clinical Practice 86, S22-S25
CrossRef521
Alan Cole, David M. Nathan, Elizabeth Savaria-Porter, Paul Copeland, Alexander Turchin, Melanie Brunt, Randall Zusman, Jo-Ann Barrett, Deborah Wexler, Emily Case, Graham T. McMahon, Elizabeth Mort. (2009) An Algorithm for the Care of Type 2 Diabetes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:4, 156-165
CrossRef522
Stephen C. Bain. (2009) Treatment of Type 2 Diabetes Mellitus with Orally Administered Agents: Advances in Combination Therapy. Endocrine Practice 15:7, 750-762
CrossRef523
Scott Drab. (2009) Translating clinical guidelines into clinical practice: Role of the pharmacist in type 2 diabetes management. Journal of the American Pharmacists Association 49:6, e152-e162
CrossRef524
A. J. Garber. (2009) Restaging insulin therapy for patients with type 2 diabetes. Diabetes, Obesity and Metabolism 11, 1-5
CrossRef525
(2009) Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation 9, S1-S155
CrossRef526
, B. E. Galan, S. Zoungas, J. Chalmers, C. Anderson, C. Dufouil, A. Pillai, M. Cooper, D. E. Grobbee, M. Hackett, P. Hamet, S. R. Heller, L. Lisheng, S. MacMahon, G. Mancia, B. Neal, C. Y. Pan, A. Patel, N. Poulter, F. Travert, M. Woodward. (2009) Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 52:11, 2328-2336
CrossRef527
F. M. Turnbull, C. Abraira, R. J. Anderson, R. P. Byington, J. P. Chalmers, W. C. Duckworth, G. W. Evans, H. C. Gerstein, R. R. Holman, T. E. Moritz, B. C. Neal, T. Ninomiya, A. A. Patel, S. K. Paul, F. Travert, M. Woodward. (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:11, 2288-2298
CrossRef528
Kerry D. Mansell, David F. Blackburn, Dean T. Eurich. (2009) Do postprandial glucose levels add important clinical information when fasting glucose levels are near normal in non-insulin-dependent patients with type 2 diabetes?. Canadian Pharmacists Journal 142:6, 298-302
CrossRef529
David Rigau Comas, José Álvarez-Sabin, Antonio Gil Núñez, Sonia Abilleira Castells, Francesc Xavier Borras Pérez, Pedro Armario García, Enrique Arrieta Antón, Eugenio Marañón Fernández, Juan Carlos Martí Canales, Ana Morales Ortiz, Juan Carlos Reverter Calatayud, Esther Sancristóbal Velasco, Ivan Solà Arnau, Pablo Alonso Coello. (2009) Guía de práctica clínica sobre prevención primaria y secundaria del ictus. Medicina Clínica 133:19, 754-762
CrossRef530
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, 2121-2158
CrossRef531
B. H. R. Wolffenbuttel, L. J. Klaff, R. Bhushan, J. L. Fahrbach, H. Jiang, S. Martin. (2009) Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabetic Medicine 26:11, 1147-1155
CrossRef532
Christine T. Cigolle, Caroline S. Blaum, Jeffrey B. Halter. (2009) Diabetes and Cardiovascular Disease Prevention in Older Adults. Clinics in Geriatric Medicine 25:4, 607-641
CrossRef533
Christian Lerch, Bernd Richter. (2009) Extent of glycemic control in type 2 diabetes mellitus: Close, but no cigar. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 593-595
CrossRef534
E. Mannucci, M. Monami, C. Lamanna, F. Gori, N. Marchionni. (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 604-612
CrossRef535
Richard E. Pratley, Thérèse McCall, Penny R. Fleck, Craig A. Wilson, Qais Mekki. (2009) Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. Journal of the American Geriatrics Society 57:11, 2011-2019
CrossRef536
S. D. Ye, M. Zheng, L. L. Zhao, Y. Qian, X. M. Yao, A. Ren, S. M. Li, C. Y. Jing. (2009) Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy. European Journal of Clinical Investigation 39:11, 980-985
CrossRef537
J. Ma, W. Yang, N. Fang, W. Zhu, M. Wei. (2009) The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 596-603
CrossRef538
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Jørn Wetterslev, Bianca Hemmingsen. 2009. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef539
D. C. W. Lau. (2009) Dietary cholesterol and other nutritional considerations in people with diabetes. International Journal of Clinical Practice 63, 15-21
CrossRef540
A. Liebl. (2009) Insulin intensification â the rationale and the target. International Journal of Clinical Practice 63, 1-5
CrossRef541
S. Jabbour. (2009) Type 2 diabetes and HbA1c goal: time for individualised therapy. International Journal of Clinical Practice 63:10, 1408-1409
CrossRef542
George G. Rhoads, Mikhail Kosiborod, Richard W. Nesto, Vivian A. Fonseca, Shou-En Lu, Quanwu Zhang, Joanne M. Foody. (2009) Comparison of Incidence of Acute Myocardial Infarction in Patients With Type 2 Diabetes Mellitus Following Initiation of Neutral Protamine Hagedorn Insulin Versus Insulin Glargine. The American Journal of Cardiology 104:7, 910-916
CrossRef543
Dirk Sander, Mark T. Kearney. (2009) Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology 256:10, 1603-1619
CrossRef544
Brian F. Leas, Bettina Berman, Kathryn M. Kash, Albert G. Crawford, Richard W. Toner, Neil I. Goldfarb, David B. Nash. (2009) Quality Measurement in Diabetes Care. Population Health Management 12:5, 265-271
CrossRef545
R. Peter, G. Dunseath, S. D. Luzio, R. Chudleigh, S. R. Choudhury, D. R. Owens. (2009) Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA 1c in subjects with Type 2 diabetes. Diabetic Medicine 26:10, 974-980
CrossRef546
, J. W. J. Beulens, A. Patel, J. R. Vingerling, J. K. Cruickshank, A. D. Hughes, A. Stanton, J. Lu, S. A. McG Thom, D. E. Grobbee, R. P. Stolk. (2009) Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 52:10, 2027-2036
CrossRef547
G. A. Thomson, R. Craig. (2009) Where now for insulin glargine - a time for pragmatic medicine?. International Journal of Clinical Practice 63:10, 1413-1415
CrossRef548
A. J. Scheen, M. H. Tan, D. J. Betteridge, K. Birkeland, O. Schmitz, B. Charbonnel, . (2009) Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabetic Medicine 26:10, 1033-1039
CrossRef549
Natale Vazzana, Francesca Santilli, Chiara Cuccurullo, Giovanni Davì. (2009) Soluble forms of RAGE in internal medicine. Internal and Emergency Medicine 4:5, 389-401
CrossRef550
Christian Weber, Oliver Schnell. (2009) The Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview. Diabetes Technology & Therapeutics 11:10, 623-633
CrossRef551
Julia Szendroedi, Marek Chmelik, Albrecht Ingo Schmid, Peter Nowotny, Attila Brehm, Martin Krssak, Ewald Moser, Michael Roden. (2009) Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 50:4, 1079-1086
CrossRef552
Kristian B. Filion, Lawrence Joseph, Jean-François Boivin, Samy Suissa, James M. Brophy. (2009) Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiology and Drug Safety 18:10, 973-976
CrossRef553
Jan Cederholm, Björn Zethelius, Peter M. Nilsson, Katarina Eeg-Olofsson, Björn Eliasson, Soffia Gudbjörnsdottir. (2009) Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diabetes Research and Clinical Practice 86:1, 74-81
CrossRef554
George Steiner. (2009) How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD. Cardiovascular Drugs and Therapy 23:5, 403-408
CrossRef555
D. S. Lasserson, P. Glasziou, R. Perera, R. R. Holman, A. J. Farmer. (2009) Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52:10, 1990-2000
CrossRef556
David C. W. Lau. (2009) Le cholestérol alimentaire et autres considérations nutritionnelles chez les personnes atteintes de diabète. International Journal of Clinical Practice 63, 44-51
CrossRef557
Anthony L. McCall. (2009) When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?. Current Diabetes Reports 9:5, 325-328
CrossRef558
Isabelle Bourdel-Marchasson, J. Doucet, B. Bauduceau, G. Berrut, J. -F. Blickle, P. Brocker, T. Constans, A. Fagot-Campagna, E. Kaloustian, V. Lassmann-Vague, P. Lecomte, D. Simon, D. Tessier, C. Verny, U. M. Vischer. (2009) Key priorities in managing glucose control in older people with diabetes. The Journal of Nutrition, Health and Aging 13:8, 685-691
CrossRef559
S. Akalin, K. Berntorp, A. Ceriello, A. K. Das, E. S. Kilpatrick, T. Koblik, C. S. Munichoodappa, C. Y. Pan, W. Rosenthall, M. Shestakova, B. Wolnik, V. Woo, W. Y. Yang, M. T. Yilmaz, . (2009) Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. International Journal of Clinical Practice 63:10, 1421-1425
CrossRef560
Baqiyyah Conway, Rhobert W. Evans, Linda Fried, Sheryl Kelsey, Daniel Edmundowicz, Trevor J. Orchard. (2009) Free fatty acids are associated with pulse pressure in women, but not men, with type 1 diabetes mellitus. Metabolism 58:9, 1215-1221
CrossRef561
Richard M. Cubbon, Matthew B. Kahn, Stephen B. Wheatcroft. (2009) Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clinical Science 117:5, 173-190
CrossRef562
Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
CrossRef563
Stuart W. Zarich. (2009) Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nature Reviews Endocrinology 5:9, 500-506
CrossRef564
Philip Raskin, Titus Gylvin, Wayne Weng, Louis Chaykin. (2009) Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews 25:6, 542-548
CrossRef565
Aaron P. Schulman, Federica del Genio, Naina Sinha, Francesco Rubino. (2009) "Metabolic" Surgery for Treatment of Type 2 Diabetes Mellitus. Endocrine Practice 15:6, 624-631
CrossRef566
M. Fisher. (2009) Improving cardiovascular risk - applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. International Journal of Clinical Practice 63:9, 1354-1368
CrossRef567
William T. Cefalu. (2009) Diabetes: HOME reveals new data on a cornerstone of treatment. Nature Reviews Endocrinology 5:9, 478-479
CrossRef568
Sunder Mudaliar. (2009) Serum glucose control in diabetic patients with cardiovascular disease: Should we be less aggressive?. Current Atherosclerosis Reports 11:5, 384-390
CrossRef569
A. S. Wierzbicki. (2009) Storms, tea cups and the adverse effects of statins. International Journal of Clinical Practice 63:9, 1268-1270
CrossRef570
DR Owens, J Rosenstock, GB Bolli. (2009) Insulin glargine and cancer: cause and effect unproven. Practical Diabetes International 26:7, 256-257
CrossRef571
P. Conthe, J. Szymaniec. (2009) De los algoritmos a la práctica clínica en el manejo óptimo del paciente diabético. Revista Clínica Española 209, 18-27
CrossRef572
J.-P. Riveline, J. Teynie, S. Belmouaz, S. Franc, D. Dardari, M. Bauwens, V. Caudwell, S. Ragot, F. Bridoux, G. Charpentier, R. Marechaud, S. Hadjadj. (2009) Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrology Dialysis Transplantation 24:9, 2866-2871
CrossRef573
Ke-Ke Jin, Lei Chen, Jing-Ye Pan, Jian-Min Li, Yang Wang, Fang-Yan Wang. (2009) Acupressure Therapy Inhibits the Development of Diabetic Complications in Chinese Patients with Type 2 Diabetes. The Journal of Alternative and Complementary Medicine 15:9, 1027-1032
CrossRef574
J. L. Sievenpiper, C. W. C. Kendall, A. Esfahani, J. M. W. Wong, A. J. Carleton, H. Y. Jiang, R. P. Bazinet, E. Vidgen, D. J. A. Jenkins. (2009) Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia 52:8, 1479-1495
CrossRef575
X. Y. Song, S. Y. Lee, R. C. W. Ma, W. Y. So, J. H. Cai, C. Tam, V. Lam, W. Ying, M. C. Y. Ng, J. C. N. Chan. (2009) Phenotype–genotype interactions on renal function in type 2 diabetes: an analysis using structural equation modelling. Diabetologia 52:8, 1543-1553
CrossRef576
Nancy A. Thornberry, Baptist Gallwitz. (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism 23:4, 479-486
CrossRef577
Pierre-Jean Guillausseau. (2009) Intensive glucose control and cardiovascular outcomes. The Lancet 374:9689, 523-524
CrossRef578
Anthony J. Joseph, Eli A. Friedman. (2009) Diabetic Nephropathy in the Elderly. Clinics in Geriatric Medicine 25:3, 373-389
CrossRef579
Thanh T. Nguyen, Tien Yin Wong. (2009) Retinal vascular changes and diabetic retinopathy. Current Diabetes Reports 9:4, 277-283
CrossRef580
A. Kautzky-Willer, A. Handisurya. (2009) Metabolic diseases and associated complications: sex and gender matter!. European Journal of Clinical Investigation 39:8, 631-648
CrossRef581
K Lipska, SE Inzucchi, M Kosiborod, HM Krumholz. (2009) Intensive glucose control and cardiovascular outcomes. The Lancet 374:9689, 522-523
CrossRef582
V. G. Athyros, A. Hatzitolios, A. Karagiannis, T. P. Didangelos, F. Iliadis, S. Dolgyras, T. Vosnakidis, P. Vasiliadis, I. Malias, K. Tziomalos, M. Samouilidou, D. P. Mikhailidis. (2009) Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Current Medical Research and Opinion 25:8, 1931-1940
CrossRef583
José Ma Lobos Bejarano, Miguel Angel Royo-Bordonada, Carlos Brotons, Luís Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Angel Lizcano, Antonio Gil-Núñez, Fernando de Álvaro, Pedro Conthe, Emilio Luengo, Alfonso del Río, Olga Cortés, Ana de Santiago, Miguel A. Vargas, Mercedes Martínez, Vicenta Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Atención Primaria 41:8, 463.e1-463.e24
CrossRef584
R. J. MacIsaac, G. Jerums, A. J. Weekes, M. C. Thomas. (2009) Patterns of glycaemic control in Australian primary care (NEFRON 8). Internal Medicine Journal 39:8, 512-518
CrossRef585
Isabelle Bourdel-Marchasson, J. Doucet, B. Bauduceau, G. Berrut, J. -F. Blickle, P. Brocker, T. Constans, A. Fagot-Campagna, E. Kaloustian, V. Lassmann-Vague, P. Lecomte, D. Simon, D. Tessier, C. Verny, U. M. Vischer. (2009) Key priorities in managing glucose control in older people with diabetes. The Journal of Nutrition, Health and Aging
CrossRef586
Larry A. Weinrauch, Eldrin F. Lewis. (2009) Aiming for the Best Control of Glycemia in Patients With Heart Failure and Type 2 Diabetes. Journal of the American College of Cardiology 54:5, 429-431
CrossRef587
Louis Monnier, Claude Colette, David R. Owens. (2009) Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes/Metabolism Research and Reviews 25:5, 393-402
CrossRef588
Brandy Patterson, Anjali V Fields, Richard P Shannon. (2009) New insights into myocardial glucose metabolism: surviving under stress. Current Opinion in Clinical Nutrition and Metabolic Care 12:4, 424-430
CrossRef589
Amna A. Shaghouli, Baiju R. Shah. (2009) The Prescription of Insulin Pen Devices Versus Syringes for Older People with Diabetes. Diabetes Technology & Therapeutics 11:7, 439-442
CrossRef590
Dan Ziegler, Wolfgang Rathmann, Christa Meisinger, Thorsten Dickhaus, Andreas Mielck, . (2009) Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. European Journal of Pain 13:6, 582-587
CrossRef591
Jacob Ilany. (2009) Providing cardiovascular benefits with safe diabetes therapy. Therapy 6:4, 455-457
CrossRef592
Allison Hedley Dodd, Margaret S. Colby, Kristina S. Boye, Cheryl Fahlman, Sunny Kim, Ronette R. Briefel. (2009) Treatment approach and HbA 1c control among US adults with type 2 diabetes: NHANES 1999–2004*. Current Medical Research and Opinion 25:7, 1605-1613
CrossRef593
Kiwon Ban, Sonya Hui, Daniel J. Drucker, Mansoor Husain. (2009) Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies. Journal of the American Society of Hypertension 3:4, 245-259
CrossRef594
C. Morath, M. Zeier. (2009) Transplantation in type 1 diabetes. Nephrology Dialysis Transplantation 24:7, 2026-2029
CrossRef595
(2009) Journal Club. Kidney International 76:1, 6-7
CrossRef596
David M. Kendall, Robert M. Cuddihy, Richard M. Bergenstal. (2009) Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use. European Journal of Internal Medicine 20, S329-S339
CrossRef597
Sabreena Basu, Guillermo E Umpierrez. (2009) Does normalization of blood glucose reduce the rate of cardiovascular events?. Therapy 6:4, 459-461
CrossRef598
Anushka Patel, Rohina Joshi, Bastiaan de Galan. (2009) Trials of cardiovascular risk factor management in type 2 diabetes. Current Opinion in Cardiology 24:4, 288-294
CrossRef599
R. L. VanGilder, K. A. Kelly, M. D. Chua, R. L. Ptachcinski, Jason D. Huber. (2009) Administration of sesamol improved blood–brain barrier function in streptozotocin-induced diabetic rats. Experimental Brain Research 197:1, 23-34
CrossRef600
W. van Biesen, S. Van Laecke, R. Vanholder. (2009) Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrology Dialysis Transplantation 24:7, 2286-2287
CrossRef601
Rachandeep Singh, Ravi Nistala, Samy I McFarlane, Adam Whaley-Connell. (2009) Glycemic control and cardiovascular disease in a high-risk chronic kidney disease population. Therapy 6:4, 507-513
CrossRef602
Y. Kawashima, J. Chen, H. Sun, D. Lann, R. J. Hajjar, S. Yakar, D. LeRoith. (2009) Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. Diabetologia 52:7, 1434-1441
CrossRef603
CD Lathia, D Amakye, W Dai, C Girman, S Madani, J Mayne, P MacCarthy, P Pertel, L Seman, A Stoch, P Tarantino, C Webster, S Williams, JA Wagner. (2009) The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology & Therapeutics 86:1, 32-43
CrossRef604
Siobhan HM Brown, Ahmed H Abdelhafiz. (2009) Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction. Therapy 6:4, 515-529
CrossRef605
M. Odette Gore, Darren K. McGuire. (2009) Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. Current Cardiology Reports 11:4, 258-263
CrossRef606
S. Prato. (2009) Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 52:7, 1219-1226
CrossRef607
Robert R Henry, A Michael Lincoff, Sunder Mudaliar, Michael Rabbia, Cathy Chognot, Matthias Herz. (2009) Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. The Lancet 374:9684, 126-135
CrossRef608
The BARI 2D Study Group. (2009) A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine 360:24, 2503-2515
Full Text609
H.-C. Diener, C. Weimar. (2009) Update of secondary stroke prevention. Nephrology Dialysis Transplantation 24:6, 1718-1724
CrossRef610
Michael R. MacDonald, Mark C. Petrie, Miles Fisher, John J. V. McMurray. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports 6:2, 126-132
CrossRef611
M. Bartnik, F. Cosentino. (2009) Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. European Heart Journal 30:11, 1301-1304
CrossRef612
A. Ferland, P. Brassard, S. Lemieux, J. Bergeron, P. Bogaty, F. Bertrand, S. Simard, P. Poirier. (2009) Impact of high-fat /low-carbohydrate, high-, low-glycaemic index or low-caloric meals on glucose regulation during aerobic exercise in Type 2 diabetes. Diabetic Medicine 26:6, 589-595
CrossRef613
Eberhard Standl, Martin Müller, Oliver Schnell. (2009) The impact of glucose-lowering therapy on cardiovascular outcomes. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 401-411
CrossRef614
Veronique Guyomard, Phyo Kyaw Myint. (2009) Optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke. Current Treatment Options in Cardiovascular Medicine 11:3, 201-211
CrossRef615
Ole-Petter R. Hamnvik, Graham T. McMahon. (2009) Glycemic Targets for Patients with Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:3, 227-233
CrossRef616
C. J. Bailey, C. Day. (2009) Fixed-dose single tablet antidiabetic combinations. Diabetes, Obesity and Metabolism 11:6, 527-533
CrossRef617
Alethea N. Hill, Cathy Roche, Susan J. Appel. (2009) Signs of improvement. The Nurse Practitioner 34:6, 12-22
CrossRef618
P. P. Toth. (2009) Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. International Journal of Clinical Practice 63:6, 903-911
CrossRef619
José M. Lobos, Miguel Ángel Royo-Bordonada, Carlos Brotons, Luis Álvarez-Sala, Pedro Armario, Antonio Maiques, Dídac Mauricio, Susana Sans, Fernando Villar, Ángel Lizcano, Antonio Gil-Núñez, Fernando de Álvaro, Pedro Conthe, Emilio Luengo, Alfonso del Río, Olga Cortés, Ana de Santiago, Miguel A. Vargas, Mercedes Martínez, Vicenta Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Clínica e Investigación en Arteriosclerosis 21:3, 124-150
CrossRef620
Oluf PEDERSEN. (2009) Intensified multifactorial treatment of patients with Type 2 diabetes: What can be achieved and does it pay off?. Journal of Diabetes 1:2, 83-89
CrossRef621
Nanae Fukaya, Kazuki Mochizuki, Masaya Shimada, Toshinao Goda. (2009) The α-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. Nutrition 25:6, 657-667
CrossRef622
U.-M. Vischer, B. Bauduceau, I. Bourdel-Marchasson, J.-F. Blickle, T. Constans, A. Fagot-Campagna, E. Kaloustian, V. Lassman-Vague, P. Lecomte, D. Simon, D. Tessier, C. Verny, J. Doucet. (2009) A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes & Metabolism 35:3, 168-177
CrossRef623
J.M. Lobos, M.Á. Royo-Bordonada, C. Brotons, L. Álvarez-Sala, P. Armario, A. Maiques, D. Mauricio, S. Sans, F. Villar, Á. Lizcano, A. Gil-Núñez, F. de Álvaro, P. Conthe, E. Luengo, A. del Río, O. Cortés, A. de Santiago, M.A. Varga, M. Martínez, V. Lizarbe. (2009) Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. Revista Clínica Española 209:6, 279-302
CrossRef624
G. Schernthaner. (2009) Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. International Journal of Clinical Practice 63:6, 912-929
CrossRef625
Kaivan Khavandi, Ali Khavandi, Omar Asghar, Adam Greenstein, Sarah Withers, Anthony M. Heagerty, Rayaz A. Malik. (2009) Diabetic cardiomyopathy – a distinct disease?. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 347-360
CrossRef626
Chih-Chen Lu, Bang-Ping Jiann, Chun-Chin Sun, Hing-Chung Lam, Chih-Hsun Chu, Jenn-Kuen Lee. (2009) Association of Glycemic Control with Risk of Erectile Dysfunction in Men with Type 2 Diabetes. Journal of Sexual Medicine 6:6, 1719-1728
CrossRef627
Suma Dronovalli, Basil O. Burney, George L. Bakris. (2009) Glycemic control and cardiovascular disease in chronic kidney disease. Current Diabetes Reports 9:3, 243-248
CrossRef628
A. Giaccari, G. Sorice, G. Muscogiuri. (2009) Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment. Nutrition, Metabolism and Cardiovascular Diseases 19:5, 365-377
CrossRef629
István Barna. (2009) A prediabéteszhez társult hypertonia kezelése. Orvosi Hetilap 150:20, 917-923
CrossRef630
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, J. Armbrecht, M. A. Pfeffer. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation 24:5, 1663-1671
CrossRef631
M. Kellerer. (2009) Update Typ-2-Diabetes anhand ausgewählter aktueller Publikationen. Der Diabetologe 5:3, 177-189
CrossRef632
Suellen M. Curkendall, Jaime L. Natoli, Charles M. Alexander, Brian H. Nathanson, Tracy Haidar, Robert W. Dubois. (2009) Economic and Clinical Impact of Inpatient Diabetic Hypoglycemia. Endocrine Practice 15:4, 302-312
CrossRef633
Theodore Mazzone. (2009) Hyperglycaemia and coronary heart disease: the meta picture. The Lancet 373:9677, 1737-1738
CrossRef634
David Verhaert, James D. Thomas. (2009) Dysglycemia and Acute Myocardial Infarction. JACC: Cardiovascular Imaging 2:5, 600-603
CrossRef635
Cyrus DeSouza, Vivian Fonseca. (2009) Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery 8:5, 361-367
CrossRef636
Neil R Poulter. (2009) Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension 27:Suppl 1, S3-S8
CrossRef637
Norman R.C. Campbell, Nadia A. Khan, Michael D. Hill, Guy Tremblay, Marcel Lebel, Janusz Kaczorowski, Finlay A. McAlister, Richard Z. Lewanczuk, Sheldon Tobe. (2009) 2009 Canadian Hypertension Education Program recommendations: The scientific summary – an annual update. Canadian Journal of Cardiology 25:5, 271-277
CrossRef638
N. Görlitz, M. Hummel. (2009) Insulintherapie bei Intensivpatienten. Der Diabetologe 5:3, 219-229
CrossRef639
Kushwin Rajamani, Peter G Colman, Li Ping Li, James D Best, Merryn Voysey, Michael C D'Emden, Markku Laakso, John R Baker, Anthony C Keech. (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. The Lancet 373:9677, 1780-1788
CrossRef640
Sandra L. Tunis, Michael E. Minshall, Christopher Conner, John I. McCormick, Jovana Kapor, Jean-François Yale, Danielle Groleau. (2009) Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis*. Current Medical Research and Opinion 25:5, 1273-1284
CrossRef641
Paul Zimmet. (2009) Preventing diabetic complications: A primary care perspective. Diabetes Research and Clinical Practice 84:2, 107-116
CrossRef642
Bernard M.Y. Cheung, Kwok Leung Ong, Stacey S. Cherny, Pak-Chung Sham, Annette W.K. Tso, Karen S.L. Lam. (2009) Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006. The American Journal of Medicine 122:5, 443-453
CrossRef643
Luis M Ruilope, Julian Segura. (2009) Kidney protection: a key target in the management of patients with diabetes. Journal of Hypertension 27:Suppl 1, S15-S18
CrossRef644
Ramiro A Sanchez, Miryam Ayala, Hugo Baglivo, Carlos Velazquez, Guillermo Burlando, Oswaldo Kohlmann, Jorge Jimenez, Patricio López Jaramillo, Ayrton Brandao, Gloria Valdes, Luis Alcocer, Mario Bendersky, Agustín José Ramirez, Alberto Zanchetti. (2009) Latin American guidelines on hypertension*. Journal of Hypertension 27:5, 905-922
CrossRef645
Kausik K Ray, Sreenivasa Rao Kondapally Seshasai, Shanelle Wijesuriya, Rupa Sivakumaran, Sarah Nethercott, David Preiss, Sebhat Erqou, Naveed Sattar. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet 373:9677, 1765-1772
CrossRef646
G. Wolf. (2009) Diabetes und Niere – Update 2009. Der Diabetologe 5:3, 190-199
CrossRef647
Hertzel C. Gerstein. (2009) Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. Nature Reviews Endocrinology 5:5, 270-275
CrossRef648
Nigel A. Calcutt, Mark E. Cooper, Tim S. Kern, Ann Marie Schmidt. (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 8:5, 417-430
CrossRef649
Mariam P. Alexander, Tejas V. Patel, Youssef M.K. Farag, Adriana Florez, Helmut G. Rennke, Ajay K. Singh. (2009) Kidney Pathological Changes in Metabolic Syndrome: A Cross-sectional Study. American Journal of Kidney Diseases 53:5, 751-759
CrossRef650
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2009) The Year in Atherothrombosis. Journal of the American College of Cardiology 53:15, 1326-1337
CrossRef651
J. N. Basile. (2009) Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. International Journal of Clinical Practice 63:4, 656-666
CrossRef652
Mandeep Bajaj, Ishwarlal Jialal. (2009) Type 2 Diabetes Treatment and Macrovascular Complications—Fat and Sugar Make a Dangerous Soufflé. Metabolic Syndrome and Related Disorders 7:2, 79-82
CrossRef653
Stefano Del Prato. (2009) Diabetes: Genes, diabetes and cardiovascular risk prediction. Nature Reviews Endocrinology 5:4, 192-193
CrossRef654
Babak Razani, Clay F Semenkovich. (2009) Getting away from glucose: stop sugarcoating diabetes. Nature Medicine 15:4, 372-373
CrossRef655
The NICE-SUGAR Study Investigators. (2009) Intensive versus Conventional Glucose Control in Critically Ill Patients. New England Journal of Medicine 360:13, 1283-1297
Full Text656
M. Reimann, E. Bonifacio, M. Solimena, P.E.H. Schwarz, B. Ludwig, M. Hanefeld, S.R. Bornstein. (2009) An update on preventive and regenerative therapies in diabetes mellitus. Pharmacology & Therapeutics 121:3, 317-331
CrossRef657
Jost Jonas, Florian Rensch. (2009) Diabetic Macular Edema. Ophthalmology 116:3, 594-595
CrossRef658
Rohina Joshi, BE de Galan, John Chalmers, Vlado Perkovic, Anushka Patel. (2009) Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. Expert Review of Endocrinology & Metabolism 4:2, 111-118
CrossRef659
Loretta Szczotka-Flynn, Rouzbeh Ahmadian, Mireya Diaz. (2009) A Re-evaluation of the Risk of Microbial Keratitis From Overnight Contact Lens Wear Compared With Other Life Risks. Eye & Contact Lens: Science & Clinical Practice 35:2, 69-75
CrossRef660
Kay-Tee Khaw. (2009) Elevated HbA1c level: a risk factor for cardiovascular disease mortality in patients with chronic heart failure?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 130-131
CrossRef661
John Y. C. Chan, Malgorzata Leyk, Brian M. Frier, Meng H. Tan. (2009) Relationship between HbA 1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin. Diabetes/Metabolism Research and Reviews 25:3, 224-231
CrossRef662
George L. Bakris, James R. Sowers. (2009) Treatment of hypertension in patients with diabetes—an update. Journal of the American Society of Hypertension 3:2, 150-155
CrossRef663
Georgia Soldatos, Mark E Cooper. (2009) Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 138-139
CrossRef664
Emily Jane GALLAGHER, Derek LE ROITH, Zachary BLOOMGARDEN. (2009) Review of hemoglobin A1c in the management of diabetes. Journal of Diabetes 1:1, 9-17
CrossRef665
N. Younis, H. Soran, M. Hassanein. (2009) Cardiovascular disease and intensive glucose lowering in type 2 diabetes. QJM 102:4, 293-296
CrossRef666
Michelle M. Averill, Karin E. Bornfeldt. (2009) Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Current Diabetes Reports 9:1, 18-25
CrossRef667
Jayanta T. Mukherjee, Richard W. Nesto. (2009) The “legacy effect” associated with intensive glucose control in patients with type 2 diabetes. Current Diabetes Reports 9:1, 63-64
CrossRef668
P. Moulin, M. André, H. Alawi, L.C. Dos Santos, A.K. Khalid, D. Koev, R. Moore, V. Serban, B. Picandet, M. Francillard. (2009) Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: An 18 to 34-week, open-label, extension period. Diabetes & Metabolism 35:1, 64-70
CrossRef669
J. Horowitz, W. J. Remme, C. Torp-Pedersen. (2009) Clinical Trials Update from the European Society of Cardiology Congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE. Cardiovascular Drugs and Therapy 23:1, 25-29
CrossRef670
Stefan G De Hert, Philippe J Van der Linden. (2009) Clinical trials: evidence based and clinically relevant or not?. Current Opinion in Anaesthesiology 22:1, 68-70
CrossRef671
GC Hawthorne, AJ Yarnall. (2009) Recent clinical trials in diabetes – implications for managing older patients. Reviews in Clinical Gerontology 19:01, 25
CrossRef672
J. Haynes. (2009) Chronic kidney disease. InnovAiT 2:2, 92-99
CrossRef673
Stuart W. Zarich. (2009) Potential of glucose-lowering drugs to reduce cardiovascular events. Current Diabetes Reports 9:1, 87-94
CrossRef674
Edward S. Horton. (2009) Defining the Role of Basal and Prandial Insulin for Optimal Glycemic Control. Journal of the American College of Cardiology 53:5, S21-S27
CrossRef675
Travis E. Sonnett, Terri L. Levien, Joshua J. Neumiller, Brian J. Gates, Stephen M. Setter. (2009) Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 31:2, 245-259
CrossRef676
Duckworth, William, Abraira, Carlos, Moritz, Thomas, Reda, Domenic, Emanuele, Nicholas, Reaven, Peter D., Zieve, Franklin J., Marks, Jennifer, Davis, Stephen N., Hayward, Rodney, Warren, Stuart R., Goldman, Steven, McCarren, Madeline, Vitek, Mary EllenHenderson, William G., Huang, Grant D., . (2009) Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine 360:2, 129-139
Full Text677
Wineke Bakker, Etto C. Eringa, Pieter Sipkema, Victor W. M. Hinsbergh. (2009) Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell and Tissue Research 335:1, 165-189
CrossRef678
Kazunori Toyoda. (2009) Pharmacotherapy for the Secondary Prevention of Stroke. Drugs 69:6, 633-647
CrossRef679
Philip R. Liebson. (2009) Diabetes Control and Cardiovascular Risk, Part II: Intensive Glucose Control - UKPDS Follow-Up. Preventive Cardiology 12:1, 51-58
CrossRef680
Katherine R. Tuttle. (2009) More Is Not Always Better: Intensive Glycemic Control in Type 2 Diabetes. American Journal of Kidney Diseases 53:1, 12-15
CrossRef681
Yusuke Moritoh, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka, Hiroyuki Odaka. (2009) The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. European Journal of Pharmacology 602:2-3, 448-454
CrossRef682
G. Paolisso, A. J. Sinclair. (2009) Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. The Journal of Nutrition, Health and Aging
CrossRef683
Pilar Mazón-Ramos, Alberto Cordero-Fort, Juan Quiles-Granado, Josep Guindo-Soldevila. (2009) Temas de actualidad en hipertensión arterial y diabetes. Revista Española de Cardiología 62, 14-27
CrossRef684
Richard Bergenstal, Andrew Lewin, Timothy Bailey, Denise Chang, Titus Gylvin, Victor Roberts. (2009) Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Current Medical Research and Opinion 25:1, 65-75
CrossRef685
Jay S. Skyler, Richard Bergenstal, Robert O. Bonow, John Buse, Prakash Deedwania, Edwin A.M. Gale, Barbara V. Howard, M. Sue Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S. Sherwin. (2009) Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Journal of the American College of Cardiology 53:3, 298-304
CrossRef686
Kazuo Eguchi, Joji Ishikawa, Satoshi Hoshide, Thomas G. Pickering, Joseph E. Schwartz, Kazuyuki Shimada, Kazuomi Kario. (2009) Night Time Blood Pressure Variability Is a Strong Predictor for Cardiovascular Events in Patients With Type 2 Diabetes. American Journal of Hypertension 22:1, 46-51
CrossRef687
James B. Meigs, Frederick A. Masoudi. (2009) Cardiovascular disease is prevented over the long term by better blood glucose control. Current Cardiovascular Risk Reports 3:1, 33-34
CrossRef688
Daniel E. Mumme, Michelle A. Mathiason, Kara J. Kallies, Shanu N. Kothari. (2009) Effect of laparoscopic Roux-en-Y gastric bypass surgery on hemoglobin A1c levels in diabetic patients: a matched-cohort analysis. Surgery for Obesity and Related Diseases 5:1, 4-10
CrossRef689
Su Kyung Park, Mi-Kyoung Park, Ji Hye Suk, Mi Kyung Kim, Yong Ki Kim, In Ju Kim, Yang Ho Kang, Kwang Jae Lee, Hyun Seung Lee, Chang Won Lee, Bo Hyun Kim, Kyung Il Lee, Mi Kyoung Kim, Duk Kyu Kim. (2009) Cause-of-Death Trends for Diabetes Mellitus over 10 Years. Korean Diabetes Journal 33:1, 65
CrossRef690
Lars Rydén, Klas Malmberg, Linda Mellbin. (2009) Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology & Metabolism 5:1, 8-9
CrossRef691
Patrick J. O’Connor, JoAnn M. Sperl-Hillen, Thomas E. Kottke. (2009) Disease management strategies to optimize cardiovascular risk in type 2 diabetes mellitus. Current Cardiovascular Risk Reports 3:1, 71-77
CrossRef692
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, B. Zinman. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52:1, 17-30
CrossRef693
F. H. Lawler. (2009) Reasons to Exercise Caution When Considering a Screening Program for Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 84:1, 34-36
CrossRef694
A. M. Sheehy, D. B. Coursin, R. A. Gabbay. (2009) Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 84:1, 38-42
CrossRef695
Guntram Schernthaner. (2008) Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?. Nature Clinical Practice Nephrology 4:12, 656-657
CrossRef696
Denise G. Simons-Morton. (2008) The Glycemia-Cardiovascular Disease Hypothesis. Clinical and Translational Science 1:3, 185-186
CrossRef697
Robert E. Ratner, Christopher P. Cannon, Hertzel C. Gerstein, Richard W. Nesto, Patrick W. Serruys, Gerrit-Anne van Es, Nikheel S. Kolatkar, Barbara G. Kravitz, Andrew Zalewski, Peter J. Fitzgerald. (2008) Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics. American Heart Journal 156:6, 1074-1079
CrossRef698
D. Luft. (2008) Pharmakotherapie der sensomotorischen Neuropathie. Der Diabetologe 4:8, 609-618
CrossRef699
Hemanth Bolusani, R Peter, A Rees. (2008) Therapy and clinical trials: glycaemia and prevention of macroangiopathy in type 2 diabetes. Current Opinion in Lipidology 19:6, 629-630
CrossRef700
Anuradha Vivekanadan-Giri, Jeffrey H. Wang, Jaeman Byun, Subramaniam Pennathur. (2008) Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage. Reviews in Endocrine and Metabolic Disorders 9:4, 275-287
CrossRef701
Atul Tiwari. (2008) Current and emerging paradigms in the therapeutic management of atherosclerosis. Expert Opinion on Therapeutic Targets 12:12, 1523-1546
CrossRef702
David Aguilar. (2008) Management of type 2 diabetes in patients with heart failure. Current Treatment Options in Cardiovascular Medicine 10:6, 465-475
CrossRef703
Quresh Mohamed, Tien Y Wong. (2008) Emerging drugs for diabetic retinopathy. Expert Opinion on Emerging Drugs 13:4, 675-694
CrossRef704
B. Radbill, B. Murphy, D. LeRoith. (2008) Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clinic Proceedings 83:12, 1373-1381
CrossRef705
M. Haneda, A. Morikawa. (2008) Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?. Nephrology Dialysis Transplantation 24:2, 338-341
CrossRef706
G. Schernthaner. (2008) Kidney disease in diabetology: lessons from 2008. Nephrology Dialysis Transplantation 24:2, 396-399
CrossRef707
(2008) Intensive glycemic control in diabetics reduces microvascular complications. Nature Clinical Practice Cardiovascular Medicine 5:11, 674-674
CrossRef708
MW Savage. (2008) Newer agents for blood glucose control in type 2 diabetes: the NICE draft proposals. Practical Diabetes International 25:9, 353-354
CrossRef709
Andrew Farmer, Elizabeth Balman, Roger Gadsby, Jane Moffatt, Sue Cradock, Lisa McEwen, Kevin Jameson. (2008) Frequency of self-monitoring of blood glucose in patients with type 2 diabetes: association with hypoglycaemic events. Current Medical Research and Opinion 24:11, 3097-3104
CrossRef710
M. Frank. (2008) Diabetes mellitus: Besonderheiten der Insulintherapie im Alter. Der Diabetologe 4:7, 525-534
CrossRef711
Chalmers, John, Cooper, Mark E., . (2008) UKPDS and the Legacy Effect. New England Journal of Medicine 359:15, 1618-1620
Full Text712
Holman, Rury R., Paul, Sanjoy K., Bethel, M. Angelyn, Matthews, David R., Neil, H. Andrew W., . (2008) 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 359:15, 1577-1589
Full Text713
(2008) Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 359:14, 1519-1521
Full Text714
Merri Pendergrass. (2008) Does intensive glycemic control improve cardiovascular outcomes?. Nature Clinical Practice Endocrinology & Metabolism 4:10, 529-529
CrossRef715
Anthony L. McCall. (2008) Does the method of obtaining glycemic control influence cardiovascular outcomes?. Current Diabetes Reports 8:5, 341-344
CrossRef716
F. Labrousse-Lherminé, P. Gourdy. (2008) Prise en charge d’une hyperglycémie au cours d’un infarctus du myocarde. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2008:171, 26-28
CrossRef717
Goldfine, Allison B., . (2008) Assessing the Cardiovascular Safety of Diabetes Therapies. New England Journal of Medicine 359:11, 1092-1095
Full Text718
George L. Bakris, James R. Sowers, . (2008) ASH Position Paper: Treatment of Hypertension in Patients With Diabetes-An Update. The Journal of Clinical Hypertension 10:9, 707-713
CrossRef719
Allison B Goldfine. (2008) Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Current Opinion in Cardiology 23:5, 502-511
CrossRef720
M Fisher. (2008) Advances in diabetes care?. Practical Diabetes International 25:7, 258-260
CrossRef721
Philip R. Liebson. (2008) Diabetes Control and Cardiovascular Risk: ACCORD, ADVANCE, AVOID, and SANDS. Preventive Cardiology 11:4, 230-236
CrossRef722
J. M. Ritter. (2008) Chronic disease: when in doubt, consider accrual into a randomized controlled trial (RCT). British Journal of Clinical Pharmacology 66:2, 169-172
CrossRef723
Steven Kaufman. (2008) Normalization of glucose in the intensive care unit: Does one size really fit all?*. Critical Care Medicine 36:8, 2448-2449
CrossRef724
P. D. Home. (2008) Impact of the UKPDS—an overview. Diabetic Medicine 25, 2-8
CrossRef725
Hermes Florez, Jennifer Marks, Carlos Abraira. (2008) Treating diabetes in the elderly: what is the impact for cardiovascular health?. Aging Health 4:4, 333-335
CrossRef726
Ken Shaw. (2008) Institute of Diabetes for Older People: surviving a sweet old age. Practical Diabetes International 25:6, 221-222
CrossRef727
Dluhy, Robert G., McMahon, Graham T., . (2008) Intensive Glycemic Control in the ACCORD and ADVANCE Trials. New England Journal of Medicine 358:24, 2630-2633
Full Text728
Cefalu, William T., . (2008) Glycemic Targets and Cardiovascular Disease. New England Journal of Medicine 358:24, 2633-2635
Full Text729
Krumholz, Harlan M., Lee, Thomas H., . (2008) Redefining Quality — Implications of Recent Clinical Trials. New England Journal of Medicine 358:24, 2537-2539
Full Text730
Heidi Ledford. (2008) Aggressive approach to diabetes proves harmful. Nature
CrossRef731
Tae Sun Park, Hong-Sun Baek, Ji-Hyun Park. (2008) General Principles for Diabetes Mellitus Management. Journal of the Korean Medical Association 51:9, 806
CrossRef732
Willmann Liang, Calista Y.R. Tan, Lisa Ang, Nada Sallam, David J. Granville, James M. Wright, Ismail Laher. (2008) Ramipril Improves Oxidative Stress-Related Vascular Endothelial Dysfunction in db/db Mice. The Journal of Physiological Sciences 58:6, 405-411
CrossRef733
Juneyoung Lee. (2008) Meta-analysis. Journal of Korean Endocrine Society 23:6, 361
CrossRef
- Letters
